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Aim: To assess the health impact of an intervention in supermarket bakeries using fractional 
exhaled nitric oxide and other clinical endpoints for baker’s allergy and asthma after a one-
year follow-up period.  
Methods: A field randomised controlled trial of 31 bakeries initially assigned to one of two 
intervention groups (bakery mixer lid and training) (n=244) and a control group (n=93). Health 
data prior to and after the intervention included a modified ECRHS questionnaire; Phadiatop 
® and serum specific IgE to cereal flours (wheat, rye, alpha-amylase); and FeNO performed 
during the work shift using NIOX MINO®. The data of the two intervention groups was 
combined into one intervention group for the analysis. Data was analysed using STATA 
(version 12). 
Results:  The two groups were comparable with regard to age (32-33 years), proportion of 
females (55%-57%) and smoking status (38%-40%). The intervention group had a significantly 
higher prevalence of workers with atopy (42%, p=0.025), work-related chest symptoms (25%, 
p=0.044) and sensitisation to cereal flour allergens (35%, p=0.042) at baseline than the control 
group (25%, 15%, 23% respectively). At one year of follow-up, the incidence and level of 
decline of work-related ocular-nasal and chest symptoms, sensitisation status and elevated FeNO 
(FeNO >25ppb) was similar in the two groups. The mean difference in FeNO was similar across 
the two groups (2.2ppb vs 1.7ppb, p=0.860). However, when stratifying according to baseline 
FeNO >25ppb, the FeNO decline was greater in the intervention group (16.9 ppb) than in the 
control group (7.7ppb), although not statistically significant (p=0.237). Multivariate logistic 
regression models (adjusting for smoking, baseline sensitisation to cereal flour, baseline FeNO 
>25ppb) did not demonstrate an appreciable decline in FeNO (>10%) in the intervention 
compared to the control group. However, stratification according to the presence of work-
vii 
 
related ocular-nasal symptoms at baseline demonstrated a significant decline (>10%) in FeNO 
in the intervention group compared to the control group (OR=3.73, CI: 1.22-11.42). 
Conclusion: This study demonstrates some evidence of an intervention effect on exhaled nitric 
oxide (FeNO) one year after the intervention, particularly among bakers reporting work-related 
ocular-nasal symptoms at baseline. The lack of a demonstrably stronger effect on other clinical 
endpoints can be attributable to the short follow-up period.  
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ABBREVIATIONS AND ACRONYMS 
ACQ:   Asthma Control Questionnaire  
AR:   Allergic Rhinitis 
ATS:    American Thoracic Society  
BA:                              Baker’s Asthma 
ECRHS:   European Community Respiratory Health survey 
ERS:   European Respiratory Society  
FeNO:   Fractional exhaled nitric oxide 
FEV1:    Forced expiratory volume 
FVC:    Forced Vital Capacity 
HMW:   High Molecular Weight 
IQR   Interquartile Range 
LLA:   Laboratory Animal Allergens  
LMW   Low Molecular Weight 
MCT:    Methacholine Challenge Test 
GM:   Geometric Mean 
NSBH                         Non-Specific Bronchial Hyperresponsiveness  
OA:   Occupational Asthma  
OR:   Odds Ratio 
PFT:                            Pulmonary Function Test 
SD   Standard Deviation  
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PART A: PROTOCOL 
Assessing the health impact of intervention in 
supermarket bakeries using fractional exhaled nitric 
oxide (FeNO) and other clinical endpoints for baker’s 
allergy and asthma 
 
  






One of the most common contributors of occupational asthma (OA) is baker’s asthma (BA).1 
Its prevalence among bakers was estimated to be between 4-17%.2-7 Moreover, it contributes 
up to 20% of all the reported OA cases.8 Furthermore, the incidence of BA in bakers  was found 
to be between 0.3-2.46 per 1000 person-years.9 10 However, cross sectional and longitudinal 
studies have shown a positive exposure-response relationship between BA and bakery dust.2 
11-13 This suggests that reducing allergen exposure would reduce the disease burden.14-16 
There are various parameters to assess the health impact of intervention including symptoms 
severity and frequency, lung function such as forced expiratory volume in one second (FEV1) 
and non-specific bronchial hyperresponsiveness (NSBH) frequency and severity, sensitisation 
to flour dust allergen and airways inflammatory markers.17 18 Although the immune mechanism 
is still unknown, persistent NSBH after exposure cessation was found to be associated with 
ongoing airway inflammation and higher level of inflammatory cytokines in sputum.19 20 
Furthermore, airway inflammation may be an early marker of allergy.21 22 Fractional exhaled 
nitric oxide (FeNO) is a one of the widely used airway inflammatory markers which could 
assist in respiratory allergic outcomes following the introduction of intervention aimed at 
reducing allergen exposures. However, FeNO levels can be influenced by various factors, so 
its role in the clinical management of OA is still controversial.23  
Justification 
The study by Baatjies et al24 appears to be the only study that evaluated intervention to reduce 
the exposure levels to flour dust. The investigators evaluated engineering controls and training 
in dust control measures which demonstrated a significant reduction in flour dust and allergen 




exposure levels. However, no studies have been identified that evaluated the health outcomes 
as a result of introducing intervention in bakeries.  
The early detection of airway inflammation through medical surveillance, even prior to the 
emergence of symptoms, may result in a better prognosis for patients with OA and reduce the 
financial burden associated with the disease.15 25-27 FeNO is a commonly used airway 
inflammatory marker that has been studied extensively in cross sectional epidemiological 
studies with very few studies focusing on longitudinal changes in FeNO. 
Purpose and benefits 
There is limited information on the health outcomes in bakers associated with flour dust 
reduction and few studies that have evaluated the determinants of longitudinal changes in 
FeNO. The results of this study would be beneficial in: 
a) Providing recommendations to the bakery industry to protect the health of workers.  
b) Improving medical surveillance programs in the bakery industry to identify workers 
who are at risk of developing BA. 
Research questions 
a) Did the intervention used in the study by Baatjies et al24 result in improvement of the 
health outcomes in these bakers? 
b) Are the parameters used to evaluate the health outcomes useful in assessing the impact 
of the intervention?  
c) Is FeNO a useful marker to study the long-term impact of allergen exposure reduction 
in bakers? 
d) What are the most important environmental and host determinants of longitudinal 
changes in FeNO in bakers? 





Does an intervention that results in a significant reduction in flour dust levels improve health 
outcomes in bakers as measured by a reduction in work-related symptoms, sensitisation and 
fractional exhaled nitric oxide (FeNO) one year after the intervention?  
Aim 
To assess the health impact of intervention in supermarket bakeries using fractional exhaled 
nitric oxide (FeNO) and other clinical endpoints for baker’s allergy and asthma.  
Objectives 
a) To determine the prevalence of work-related symptoms, sensitisation to flour dust 
allergens and high FeNO in bakers prior to introducing an intervention to reduce flour 
dust exposure. 
b) To determine the incidence of work-related symptoms, sensitisation to flour dust 
allergens and high FeNO in bakers one year after introducing an intervention to reduce 
flour dust exposure. 
c) To compare the prevalence and incidence of work-related symptoms, sensitisation to 
flour dust allergens and high FeNO between the intervention and control groups one 
year after introducing the intervention. 
d) To investigate the impact of environmental and host factors on longitudinal changes in 
FeNO. 






This study was a randomised control field trial that involved the analysis of data that was 
collected in 2011 as a part of a larger study started in 2003 (figure 1). The original study 
identified 31 bakeries in the Western Cape Province of South Africa as the potential population 
for the study that were randomly selected into two intervention groups and one control group. 
The study was conducted in five phases.                                                                                                                                    
Phase I: Baseline exposure assessment study28 
During this phase, 18 bakeries from 31 bakeries belonging to a supermarket chain store in the 
Western Cape province were randomly selected to participate in the study. These bakeries were 
stratified based on their workforce and the products of these bakeries into small, medium and 
large size bakeries. Finally, 109 bakers were randomly selected as participants representing 
different job categories in the bakeries. A total of 211 full-shift personal samples were collected 
to measure the level of exposure to flour dust in different job categories in the bakeries. 
Phase II: Baseline health outcome parameters study3 
During this phase, a cross sectional survey of 517 workers employed in the 31 bakeries, 
belonging to the supermarket chain store participated, conducted between June 2003 and June 
2004. The study collected baseline data of work-related symptoms using a modified 
questionnaire from the European Community Respiratory Health Survey (ECRHS),29 skin 
prick tests and specific IgE to wheat, rye and fungal amylase, spirometry and MCT. 





Figure 1: Flow diagram illustrating intervention study design and bakeries assessed pre-and 
post-intervention. 
 




Phase III: Baseline work-related symptoms, sensitisation and fractional exhaled 
nitric oxide measurements prior to the intervention30 
During this phase, cross sectional survey of 424 workers of the previous cohort of 517 workers 
was conducted in 2007. There were 93 workers from the original cohort that were not traceable 
and did not participate in this phase. The study collected cross sectional data of chest 
symptoms, ocular-nasal symptoms and work-related symptoms using a short questionnaire 
(appendix 2), serum specific IgE to wheat, rye and α-amylase as well as FeNO. 
Phase IV: Assessment of the effectiveness of intervention using flour dust levels24 
During this phase, in 2010, there were 18 bakeries that participated in phase I that were assigned 
to two intervention groups and a control group, among whom 15 bakeries were evaluated. Full-
shift personal samples were again used to measure the flour dust levels in 128 workers 
representing adequately the different job categories found in these bakeries one year after 
implementing the intervention. 
Phase V: Assessment of the effectiveness of intervention using health outcome 
parameters  
In this phase, in 2011, a cross sectional survey was conducted on 361workers of which 337 
were part of the same cohort participated in phases II and III. This study collected data of work-
related symptoms using the modified ECRHS questionnaire (appendix 3), specific IgE to 
wheat, rye and fungal amylase and FeNO (appendices 4 and 5). It is the complete data collected 
in this phase on 337 workers that was analysed in this study. 
 




Population and sampling 
Study population 
The study population comprised of 361 bakery workers from 31 supermarket bakeries of a 
supermarket chain store in the Western Cape province of South Africa.  The study population 
was drawn from the 517 workers evaluated in earlier phases of the original study. These 
included 318 permanent and 168 casual workers in the bakery as well as 31 asthmatic ex-bakers 
who had been moved from the bakery section 2 years prior to the original study in June 2003. 
At follow up, 7 years later, 156 workers were not traceable for further evaluation for various 
reasons. The current cohort however represented adequately different job categories found in 
the bakery environment. It included 297 permanent and 40 casual workers. 
Sampling strategy 
The 31 bakeries were categorized into small, medium and large size based on their workforce 
volume and the types of products produced. Then, 18 bakeries were randomly selected into 3 
different arms; 6 bakeries received lid for mixer and training manual intervention, 6 received 
training manual intervention only and 6 included as a control group. They were equally selected 
to represent the 3 different size categories. All the workers of each bakery were included in the 
study.  
In the current study, 3 bakeries from the control arm were not included for various reasons 
including business reorganization. We were able to approach 361workers among whom 337 
(intervention arm n=244, control arm=93) were part of the original cohort that were eligible to 
participate in the study.  
 
 




Sample size calculation 
According to the previous phases of this study, the prevalence of pre-intervention work-related 
chest symptoms was 26%.30 We suspected a decrease in the prevalence of chest symptoms by 
50% after the introducing the intervention. Using this information, the minimum sample size 
for testing a difference between two proportions would be 160 subjects in each arm based on 










However, we were able to collect complete data from 337 subjects and, therefore, this entire 
sample was used for analysis and would, therefore, have sufficient power to assess the changes 
anticipated. Moreover, the two intervention arms were combined to create one overall 
intervention group so as to detect differences between those who received the intervention 




A standard questionnaire designed based on the protocol for the European Community 
Respiratory Health Survey (ECRHS)29 was administered to 361 workers (appendix 3). It 
gathered information on acute and chronic work-related respiratory and dermatological 
symptoms and a history of other comorbidities. It, also, covered information related to current 
and previous employment, levels of exposure to flour dust and tobacco smoke. The modified 
questionnaire was administered in either English or Afrikaans. 
 




Serum immunological tests  
Blood samples were obtained from 355 workers for Serum-specific immunoglobulin IgE. Sera 
were tested to determine for the presence of atopy using Phadiatop® test (ImmunoCAP 100 
System; Phadia, Uppsala, Sweden). The sera were also tested for specific IgE to flour dust 
allergens such as wheat (f4), rye (f5) and fungal a-amylase (k87) using fluorescence enzyme 
immunoassay (CAP-FEIA) according to the manufacturer’s instructions (Phadia).  
Fractional exhaled nitric oxide determination 
A hand-held portable nitric oxide sampling device (NIOX MINO) was used to determine FeNO 
during the work shift in 361 workers.  It was performed in a room distant from the bakery area 
during the work shift throughout the working week according to American Thoracic Society 
(ATS)/European Respiratory Society (ERS) recommendations.31 32 The testing of workers had 
no particular variation with regard to time of testing for the different jobs. The average of three 
technically adequate FeNO measurements was determined (appendices 4 and 5). Workers were 
instructed to abstain from smoking, eating or drinking at least one hour before the test. This 
was confirmed prior to testing, and those who did not follow the instructions were tested at a 
later stage after ensuring their full compliance with these instructions. 
List and definition of variables 
Outcome variables 
Outcome variables of interest for this study before the intervention 
a) Ocular-nasal symptoms related questions:  
i. Presence: “Yes” to at least one of the following 2 questions:  
- “During the past 12 months have you had two or more episodes of: sneezy, 
itchy or runny nose when you did not have a cold or flu?”  




- “During the past 12 months have you had two or more episodes of: red, itchy 
or watery eyes?” 
ii. Work-relatedness: Was assessed in response to one of the two questions: 
- “Do your nose or eye symptoms seem better or worse when you are away from 
work” 
- “Does being at work ever cause you to have sneezy/itchy runny nose or 
red/itchy/watery eyes?” 
b) Asthma related questions:  
i. Presence of asthma: 
• Doctor diagnosed asthma 
• Current asthma: “Yes” to at least one of the following 2 questions:  
- “Have you had an attack of asthma in the last 12 months?” 
- “Are you using any medicines, including inhalers/ pumps, nebulizers, 
syrups or tablets, for asthma or breathing problems?” 
ii. Work-relatedness: Was assessed in response to one of the two questions: 
- “Do your chest symptoms seem better or worse when you are away from 
work”  
- “Does being at work ever make your chest tight or wheezy? 
c) Serum-specific IgE to wheat, rye and fungal a-amylase: Results was treated as a 
continuous variable or binary variable (ImmunoCAP ≥ 0.35 kU/L). 
d) FeNO levels, was treated as a: 
i. Continuous variable (log-transformed), or 
ii. Binary variable if FeNO > 50ppb and FeNO > 25ppb.    





Outcome variables of interest for this study post the intervention 
This was assessed by computing the change in the prevalence of ocular-nasal symptoms, 
asthma symptoms, sensitisation and the level of FeNO (> 25ppb and FeNO > 50ppb) post the 
intervention. Furthermore, a >10% change in FeNO (decline) was modelled to assess the 
positive impact of the intervention in causing decreased allergic airway inflammation. 
Covariates and confounders 
The main covariate of interest was belonging to the intervention or the control arm. Potential 
confounders considered included smoking (categorical variable), atopy (binary variable based 
on Phadiotop test), age (continuous variable), corticosteroid use (categorical variable), and 
baseline FeNO as a continuous variable and a binary variable (> 25ppb).  
DATA MANAGEMENT AND ANALYSIS PLAN 
STATA statistical package (version 12) was used to analyse the data. Exploratory data analysis 
was carried to check for the presence of outliers, the extent of missing data as well as the 
distributions of the key variables and any transformation needed. Descriptive statistics was 
used to summarize each measured variable.  Data is presented as proportions, means (geometric 
where appropriate) or median and the corresponding standard deviation (SD) or 
interquartile range (IQR). Chi-square test and an independent t-test (or Fisher’s exact test and 
Wilcoxon sum rank test where appropriate) were used to compare groups at baseline as well as 
to determine the effect of intervention on the incidence and decline of allergic and respiratory 
health outcomes at one-year follow-up. Univariate linear regression was used to explore the 
determinants of longitudinal change in FeNO. Multivariate regression analysis was used to 
determine predictors of a 10% or more decline in FeNO using the intervention and adjusting 




for other confounders such as current smoking, baseline FeNO>25ppb and sensitisation to 
cereal flour allergens. 
LIMITATIONS 
a) The post intervention period may not be sufficient to detect an improvement in health 
outcome parameters. Changes in asthma symptoms and sensitisation may take more than 
one year to manifest after decreased/cessation of exposure to the offending allergens.20  
b) Loss to follow-up was approximately 35%, which may impact on the effect estimate. 
c) The sample size in the two individual arms may not be sufficient to compare the effect of 
individual intervention groups separately and would need to be combined to increase the 
power of the study. 
d) The healthy worker effect may introduce probable bias should there be differences between 
those that were no longer working in the bakeries under study. 
e) Some of the bakeries in the control group may have applied changes to their work practices, 
which may dilute the strength of the effect estimates. 
ETHICS AND COMMUNICATION 
The original study received ethical approval from the Research Ethics Committee of the 
University of Cape Town (reference No. 272/2002). This study did not collect any new data 
and the analysis was conducted on an existing data set from the original study. Therefore, the 
participants of the original study were not prone to any additional risk. However, the current 
study received ethical approval from the University of Cape Town, South Africa (appendix 6) 
The study was conducted in accordance with the World Medical Association Declaration of 
Helsinki.33  





All workers signed informed written consent before embarking on the project. Participation 
was voluntary at no cost to either the worker or the employer. 
Confidentiality  
Results of the tests with interpretation were only shared with the participants. All data was 
coded and workers’ and the company’ confidentiality was maintained. The hard copies data 
were strictly stored in in cabinets under lock and key at the School of Public Health and Family 
medicine at University of Cape Town. Furthermore, the data was archived on computer with 
limited access to researchers only. Only summary data was presented for public presentations. 
Personal information was only released with the worker's consent, should the need have arisen, 
to their family doctor or the occupational health clinic. 
Benefits  
Study participants were informed of their tests results. Those who had abnormal results were 
offered referral for further evaluation to the Occupational Medicine Clinic at Groote Schuur 
Hospital. All confirmed cases of occupational diseases have been managed medically, had 
compensation claims submitted and a medical advice for relocation has been sent to the 
employer.  
Although this study may not add direct benefits for the participants, the findings of the analysis 
will provide more information about the usefulness of intervention aimed at reducing the flour 
dust exposure on various health outcomes in bakers. It will also provide information on the 
usefulness of using FeNO in medical surveillance programs of bakers to identify those at high 
risk of developing baker’s asthma. 





The original study had negligible risk to the participants except the mild discomfort from the 
needle prick during blood sample collections. Furthermore, there was no additional risk to the 
participants since the current study did not require their active physical participation since data 
had already been collected. 
Justice 
The reported health problems and disease burden among bakers justified the need for the study 
as to find ways to reduce the disease burden and improve the quality of life of these workers. 
Dissemination of the research results 
The results of the study will be disseminated in various forms 
a) MMed dissertation to be submitted to the University of Cape Town 
b) Academic seminars, research forums and local/international conferences  
c) Publications in local and peer reviewed scientific journals 
d) Report to the relevant stakeholders 
Funding  
There was no additional funding required for this sub-study, which was originally funded by  
research scholarship grants from the Center for Asthma in the Workplace (Montreal, Canada), 
Medical Research Council (Republic of South Africa), the National Research Foundation 
FA2006040700028 (Republic of South Africa), the Fogarty International Centre (Bethesda, 
Maryland, USA), the Allergy Society of South Africa (Cape Town) and University of Cape 
Town Research Committee (Cape Town) and the baking industry (Cape Town). 
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It has been well documented that the major hallmarks of asthma are the presence of airway 
inflammation, variable airway obstruction and airway hyperresponsiveness (AHR).1 Among 
this triad, airway inflammation appears to be increasingly recognised as a major component in 
the initiation and long-term progression of the disease. There are several methods of measuring 
airway inflammation in asthma, one being the measurement of fractional exhaled nitric oxide 
(FeNO) as a marker for asthma in symptomatic individuals.2 FeNO is a non-invasive marker 
that has been extensively investigated in several contexts such as diagnosis, initiating 
treatment, tailoring medication, achieving asthma control and predicting future relapses of 
asthma. Various studies have demonstrated that FeNO is affected by individual host attributes 
and environmental factors. FeNO levels at baseline are reported to be higher in men and levels 
increase with height, atopy, dietary intake of food rich in nitrates, allergen exposures causing 
sensitisation and viral airway infections.3-6 FeNO levels can be decreased with 
bronchoconstriction, inhaled corticosteroid therapy and among both active and passive 
smokers.3-6 Most of the studies on the determinants of baseline FeNO have focused on the 
asthmatic population and fewer studies having evaluated serial changes in FeNO in the general 
population or in occupational contexts over longer periods of time. 
OBJECTIVES OF THE LITERATURE REVIEW 
The aim of this review was to  
a) Identify the determinants of serial longitudinal changes in FeNO. 
b) Determine the usefulness of different interventions in decreasing airway inflammation 
measured by FeNO. 
c) Determine the usefulness of using FeNO in monitoring workers with persistent 
exposures to respiratory sensitisers. 




LITERATURE REVIEW STRATEGY 
Due to the paucity of studies on this subject, it included all relevant epidemiological or 
experimental studies on asthmatic children or adults having a direct or indirect allergen 
exposure modulation component that were published in English between January 1999 and 
April 2017. Articles were retrieved from PubMed/Medline and Google Scholar. The key search 
terms that were used in this review were “asthma”, “FeNO” OR “exhaled nitric oxide” AND 
“serial” OR “longitudinal”. Furthermore, some articles were retrieved using the functions 
“similar articles search” in PubMed and “related articles” in Google Scholar as well relevant 
articles that were cited in the references of these articles. Clinical studies that focused on the 
effect of medication or inhalation challenge test on FeNO in patients were excluded from this 
review. 
The review identified various factors associated with longitudinal changes in FeNO in 20 
studies as outlined in Tables 1-3. The articles were summarized according to the population of 
interest. Eight of the studies were experimental in design with six being quasi-experimental 
studies and two being non-randomised controlled trials. Furthermore, there were ten 
epidemiological studies (five longitudinal, four case-control, and one cross sectional) and two 
clinical case reports. Most of the studies focused on asthmatic populations but two studies also 
evaluated FeNO in working populations with exposure to respiratory sensitisers. 
ENVIRONMENTAL FACTORS 
Allergen exposure 
Various studies using specific inhalation challenges (SIC) of suspected allergens in general 
asthmatic patients have shown that it takes up to 8 hours before FeNO starts to increase and it 
continues to remain elevated for up to 48 hours7 8 and in some studies up to 72 hours.9 10 In 




patients suspected of having occupational asthma, most studies have reported changing FeNO 
levels 20-24 hours post SIC10-17 and showed a significant increase in FeNO.2  
Exposure to the relevant allergen in asthmatic populations has been shown to demonstrate 
positive associations with longitudinal changes in FeNO. Baraldi et al18 in their case-control 
study investigating the association between serial FeNO and exposure to grass pollens in atopic 
asthmatic children sensitised to grass pollen found that exposure in the pollen season led to a 
two-fold increase in the overall mean FeNO levels, which returned to baseline after the season. 
This association between exposure to pollen during the pollen season and to other allergens 
was also reported by Roberts et al19 Spanier et al20 and Cutts et al21. However, Fowler et al22 
found a negative association between allergen exposure and FeNO (-1.5-fold, 95% CI -1.2 – -
1.7-fold). Since exposure was not monitored during the long study period (mean duration was 
47 months), there may have been changes in the exposure level over this period that may have 
introduced bias in the study.  
Ongoing exposure to an occupational allergen appears to be one of the determinants of 
longitudinal change in FeNO. Van der Walt et al evaluated serial FeNO associated with 
occupational exposure to spices in 150 mill workers after a two days exposure free period 
during time off work.11 There was no significant difference in the overall mean FeNO between 
baseline, after the shift and 24 hours after the baseline pre-shift level. However, there was a 
>12% increase in FeNO across the 24-hour period in 23% of the workers. The authors 
concluded that exposure to the spice allergens in this occupational setting was associated with 
a delayed increase in FeNO from the baseline. Hewitt et al also evaluated serial FeNO among 
workers exposed to laboratory animal allergens (LAA).34 The investigators studied 50 animal 
laboratory workers for five working days after being off work for two days. There was a 
progressive increase in FeNO (>100 ppb) over the working week in one subject who was 
seropositive to one or more of the LAA. Furthermore, three additional subjects (one 




seropositive with lifelong asthma plus two who were seronegative) experienced >25 ppb 
fluctuation in FeNO during the working day in the period of observation. However, the mean 
symptoms score for the four subjects did not differ from the mean symptoms score obtained 
for the others. Interestingly, the subject that demonstrated progressive increase in FeNO 
developed typical asthma symptoms six months after the study and was later diagnosed with 
occupational asthma based on previous positive serology, development of airway hyper-
responsiveness and increased FeNO. Both  studies were conducted in worker populations 
comprising both asymptomatic and symptomatic individuals.  
Allergen exposure avoidance 
Avoidance of exposure to the suspected common aeroallergen has also been studied in 
asthmatic children. Piacentini et al23 studied the outcome of allergen avoidance at 1756 m 
above sea level for three months in 20 asthmatic children who were sensitised to house dust 
mite (HDM). FeNO levels decreased progressively in the first 2 weeks (p = 0.014) and 
remained unchanged for the next three months. This drop in FeNO was also reported by Peroni 
et al25 in HDM sensitised asthmatic children living at high altitudes for 9 months. The mean 
FeNO levels decreased by 50% in the first 3 months (p = 0.030), but there was no further 
significant change over the remaining period. Huss-Marp et al have argued that avoidance of 
the allergen is not the only contributing factor in the decline of FeNO observed in these studies, 
suggesting that physiological changes at high altitude may also contribute to this.26 37 This study 
found that FeNO declined significantly in HDM sensitised asthmatic children as a group and 
in the non-HDM sensitised group or those with intrinsic asthma, but no significant difference 
in the reduction between the two groups was observed. Karagiannidis et al38 also reported a 
similar conclusion. It is however likely that there may have been residual exposure to HDM at 
this lower altitude compared to the Piacentini and Peroni studies that were done at higher 
altitudes. Furthermore, it is possible that by combining subjects who were sensitised to 




allergens other than HDM (n = 251) and those with intrinsic asthma (n = 22), this may have 
confounded the findings.  
In the occupational context, Merget evaluated the effect of avoidance of exposure to inhalant 
allergens in two case studies.35 36 A sensitised farmer to triticale and a mildly sensitised baker 
to wheat and rye, both demonstrated a decrease in FeNO after avoidance of the potential 
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Table 1: Experimental studies of serial longitudinal FeNO measurement among asthmatics in the general population (children and adults) 
Table 1A. Studies among children 
AUTHORS Piacentini et al, 199923 Piacentini et al, 200124 Peroni et al, 200225 
AIM OF STUDY To evaluate the effect of house 
dust mite (HDM) avoidance in 
allergic asthmatic patients on 
FeNO. 
To determine the relationship 
between exposure level to house 
dust mite (HDM) allergen and the 
magnitude of exhaled FeNO after 
allergen avoidance in a group of 
allergic asthmatic children. 
To study the change in lung 
volumes and airway 
inflammatory markers in house 
dust mite (HDM) sensitised 
asthmatic children resident in an 
allergen free environment. 
STUDY DESIGN Quasi-experimental Quasi-experimental Quasi-experimental 
STUDY POPULATION 20 Italian asthmatic children (6 to 
15 years) sensitised to HDM. 
Thirteen received regular courses 
of inhaled corticosteroids (ICS). 
14 Italian asthmatic children (6 to 
15 years) sensitised to HDM. 
18 asthmatic children who have 
moderate to severe asthma and 
sensitised to HDM  




AUTHORS Piacentini et al, 199923 Piacentini et al, 200124 Peroni et al, 200225 
INTERVENTION Avoidance of HDM by staying at 
1756 m above sea level in the 
Italian Alps for 3 months. 
Avoidance of HDM by staying at 
1756 m above sea level in the 
Italian Alps for 3 months. 
Avoidance of HDM by staying at 
1756 m above sea level in the 
Italian Alps for 9 months between 
September and June. 
OUTCOME 
MEASURES 
Change in FeNO level. • The level of HDM group I 
allergen at home. 
• Change in FeNO. 
FeNO, lung function. 
MEASURMENTS 
 
• FeNO was measured daily, 
always at the same hour 
starting at the parents’ house 
(T0), for 2 weeks after 
moving to the residential 
home until day 15 (T1), after 
3 months at the residential 
• Children received a regular 
course of ICS for at least 3 
months at the beginning of the 
study. The ICS course was 
gradually withdrawn in all the 
subjects. By T1, none of the 
• Measurements taken (i) 
within 3 days of admission, 
(ii) after 3 months of stay, (iii) 
within 2 days before leaving 
the residential home for the 
Christmas holiday, (iv) on 
return to the residential home 




campus (T2), and, in 10 of the 
20 patients, 2 weeks after 
return to their parents at sea 
level (T3). 
• FEV1 is measured at T0, T1, 
T2, and T3.  
• Serum eosinophil cationic 
protein (ECP) was measured 
at T0, T2, and T3. 
children received any ICS for 
1 month at least. 
• FeNO was measured at the 
parent’s home (T0) and after 
3 months at the residential 
campus (T1). 
after 15 days at home and (v) 
at the end of the camp after 9 
months of staying at 
residential home. 
• ICS were withdrawn after few 
weeks of admission, resumed 
during the Christmas holiday 
and withdrawn again during 
the rest of the study. 
RESULTS • FeNO decreased (p=0.014 at 
T1) with a significant effect of 
the time in the first 2 weeks 
(p=0.026). It didn’t change in 
the period T1 to T2, and 
returned to T0 level at 
(p=0.004, T2 vs T3). 
Strong correlation between the 
change in FeNO (T0-T1) and the 
levels of HDM antigens in the 
beds of the patients before T0; 
r=0.618 (p=0.026). 
• FeNO decreased from (21.3 ± 
3.9 ppb) in September to (11.9 
± 1.7 ppb) in December 
(p=0.03). No significant 
change after the holiday in 
January (12.5 ± 2.6 ppb) nor 




• FeNO did not change 
significantly from T1 to T2, 
despite the withdrawal of 
ICS. 
• FEV1 improved gradually. 
at the end in June (13.2 ± 2.0 
ppb). 
• The RV to TLC ratio 
decreased between September 
and December (p=0.003), 
increased between December 
and January (p=0.002) and 
decreased again between 
January and June (p=0.002). 
• No significant correlation 










AUTHORS • Piacentini et al, 1999
23 • Piacentini et al, 200124 • Peroni et al, 200225 
LIMITATIONS • Absence of a control group at 
sea level. 
• Small sample size. 
• Independent effect of high 
altitude on FeNO levels. 
• No mention of important 
confounders (passive 
smoking and diet). 
• Absence of a control group at 
sea level. 
• Small sample size. 
• Independent effect of high 
altitude on FeNO levels. 
• No mention of important 
confounders (passive 
smoking and diet). 
• Absence of a control group at 
sea level. 
• Small sample size. 
• Independent effect of high 
altitude on FeNO levels. 
• No mention of important 
confounders (passive 
smoking and diet). 
CONCLUSION FeNO levels decreased over time 
after the avoidance of the 
potential allergen in allergic 
asthmatic children. 
FeNO reduction after the 
avoidance of the potential 
allergen correlated with the 
magnitude of the exposure of the 
allergen prior to avoidance.  
Allergen avoidance at high 
altitudes led to a reduction in 
FeNO levels in asthmatic children 
sensitised to HDM. 
 
  




Table 1A. Studies among children (continued) 
AUTHORS Huss-Marp et al, 200726 Kaminsky et al, 200827 Saito et al, 201328 
AIM OF STUDY To study the effect of rehabilitation of 
asthmatic children at high altitudes and 
HDM avoidance on asthma control. 
To study the effect of attending an 
asthma summer camp on airway 
inflammation as measured by 
FeNO. 
• To examine whether an 
asthma education program is 
associated with asthma 
control. 
• To compare absolute levels 
and changes of ACT score, 
FEV1, and FeNO over a year 
after the intervention. 
• To evaluate FeNO as a 
marker of asthma control 
compared to other methods. 
 
STUDY DESIGN Quasi-experimental Quasi-experimental Quasi-experimental 




AUTHORS Huss-Marp et al, 200726 Kaminsky et al, 200827 • Saito et al, 2013
28 
STUDY POPULATION 311 asthmatic children with increased 
FeNO levels at admission (>17 ppb). 
 
27 asthmatic children  • 12 mild, 21 moderate, and 17 
severe persistent asthmatic 
adult patients (n=50) with 
poor adherence to 
medication. 
INTERVENTION Rehabilitation at 1200 m above sea 
level in the Bavarian Alps.  
Participation in a one-week camp 
during the summer of 2006 in the 
USA. 
Asthma education program 
providing information about 
asthma pathogenesis, diagnosis, 
severity, medications (including 
side effects), differences between 
reliever and controller agents, 
importance of asthma treatment, 
inhaler device instructions, 
exacerbation management, peak 




expiratory flow (PEF) 
monitoring, and a self-
management plan. 
OUTCOME MEASURES Change in FeNO level. FeNO, lung function and ACQ 
score. 
Change of ACT score, FeNO and 
spirometry levels over time. 
MEASURMENTS 
 
• Subjects were grouped according to 
asthma severity based on the 
clinical features before therapy 
from grade I (mild intermittent) to 
3 levels of persistent asthma 
(grades II-IV: mild, moderate, and 
severe, respectively; grade I: n=67; 
grade II: n=135; grade III: n=104; 
grade IV: n=5). 
• FeNO, FEV1 and ACQ score 
were measured at the 
beginning and end of the 
week. ACQ score was also 
obtained at one month and 6 
months after the camp. 
• The children participated in 
daily educational activities 
about asthma.  
• Subjects were reviewed four 
times: at entry and at intervals 
of 3, 6 and 12 months. 
• Treatment was not changed in 
the first 3 months to study the 
effect of the educational 
program on asthma control. 
Thereafter, the treatment 
could be changed according 
to the GINA guidelines.  




• FeNO measurement was performed 
on the day of admission and at 
discharge (4-6 weeks). 
• During the follow-up period, 
subjects were divided into 
two groups:  
- Stable group: treatment had 
not changed or was decreased 
over the study period. 
- Unstable group: increase in 
ICS dose or other anti-
asthmatic drugs added during 
the study period. 
RESULTS • 47.2 % reduction in the mean FeNO 
of all 311 children after 
rehabilitation, with 38.5 ± 22.8 ppb 
at admission compared to 20.1 ± 
13.2 ppb at discharge (p<0.001). 
• FeNO dropped significantly 
by 45% (p <0.001), but the 
changes in lung function and 
ACQ was not statistically 
significant.  
• Decrease in FeNO and 
increase in ACT scores in the 
stable asthma group (n=42) 
compared to the unstable 
asthma group (n=8); 
(p<0.001) and remained 




• FeNO reduction was significant in 
all subgroups and most marked in 
children with mild asthma. 
• FeNO reduction in asthmatics with 
isolated HDM sensitisation was no 
different to the reduction in other 
children sensitised to other 
allergens. 
• Among the 21 children 
prescribed with ICS, 18 had 
decreased FeNO and 3 had 
increased FeNO.  
• Among the 4 children not 
prescribed any ICS, 3 had 
decreased FeNO, and 1 had an 
increase in FeNO. 
consistent in the stable group 
over the course of 12 months. 
• Significant correlations 
between change in FeNO, 
ACT score and FEV1 in all 
four visits. 
LIMITATIONS • Absence of a control group at sea 
level. 
• HDM concentrations in the 
rehabilitation center not reported.  
• Independent effect of high altitude 
on FeNO levels. 
• Small sample size. 
• First day measurements were 
conducted in the afternoon and 
the final day measurements in 
the morning. 
 
• Selection bias. 
• Hawthorne effect. 
 




• No mention of important 
confounders (passive smoking and 
diet). 
CONCLUSION FeNO decreased significantly after 4-6 
weeks rehabilitation at high altitude, 
which could be explained by allergen 
avoidance, absence of air pollution and 
improved compliance to medication. 
FeNO levels declined after 
attendance of a one-week asthma 
summer camp, despite no changes 
in lung function or asthma control, 
which could be explained by 
allergen avoidance, absence of 
exposure to tobacco smoke, and 
avoidance of psychosocial 
stressors.  
• FeNO levels declined after an 
asthma education program 
and remained significant over 
a year.  
• Change in FeNO levels 
correlated significantly with 
change in ACT score and 
change in FEV1 levels. 
 
  




Table 1B. Studies among adult working population 
AUTHORS Dressel et al, 200729 Dressel et al, 200930 
AIM OF STUDY To assess whether FeNO is useful in detecting a 
reduction in airway inflammation within a few 
weeks of an educational intervention in farmers with 
occupational asthma. 
To determine whether long-term changes in FeNO 
could be detectable a year after an intervention. 
STUDY DESIGN Non-randomised controlled trial Non-randomised controlled trial 
STUDY POPULATION Cases: 81 animal farmers with occupational asthma 
sensitised to cow dander and storage mites who 
participated in a 1-day educational program. 
Controls: 24 animal farmers with occupational 
asthma not subjected to an intervention. 
• Cases: animal farmers with occupational asthma 
(n=43) who participated in a 1-day educational 
program. 
• Control: animal farmers with occupational asthma 
(n=15) not subjected to an intervention. 
INTERVENTION A one-day educational program provided general 
information about the pathogenesis of asthma and 
allergies, environmental influences, treatment, 
A one-day educational program provided general 
information about the pathogenesis of asthma and 
allergies, environmental influences, treatment, major 




major occupational allergens causing asthma, 
particularly cow dander and mites, and prevention 
methods in the workplace. 
occupational allergens causing asthma, particularly 




FeNO, lung function and a questionnaire. FeNO, lung function and a questionnaire. 
MEASURMENTS 
 
Baseline FeNO measurement and repeated 4–6 
weeks after the intervention. 
Baseline FeNO measurement and repeated one year 
after the intervention. 
RESULTS • There was a decline in the proportion of subjects 
reporting at least one current respiratory 
symptom at work (p=0.012) in the intervention 
group. 
• The geometric mean FeNO decreased from 28.2 
to 25.7 ppb (p= 0.042). 
• Geometric mean ± SEM of FeNO decreased from 
(31.5±1.1) to (25±1.1) ppb in the intervention group 
(p=0.001), while it showed a slight but statistically 
insignificant increase in the control group 
(p=0.258) 
• FEV1 and FEV1/FVC did not significantly change 
over time in either group. 




• Subjects with a baseline FeNO of >35 ppb 
(n=32), FeNO decreased from 59.7 to 49.2 ppb 
(p=0.003). 
• There was no significant change in the 
spirometry after the intervention. 
LIMITATIONS • Selection bias. 
• No mention of important confounders (atopy and 
diet). 
• Selection bias. 
• No mention of important confounders (atopy and 
diet). 
CONCLUSION FeNO showed a significant short-term reduction 
after an educational intervention in animal farmers 
with workplace-related allergic asthma, which was 
accompanied by decrease of frequency of 
symptoms. 
FeNO showed a significant long-term reduction after an 
educational intervention in animal farmers with 
workplace-related allergic asthma, which may be 
explained by a reduction in allergen exposure.  
 
  




Table 2: Epidemiological studies of serial longitudinal FeNO measurement among asthmatic children. 
AUTHORS Barreto et al, 200831 Baraldy et al, 199918 
AIM OF STUDY To assess variations and reproducibility of FeNO in 
subjects maintained under similar environmental 
conditions. 
• To evaluate the relationship between natural 
allergen exposure to grass pollen and the changes 
in FeNO in atopic asthmatic children during and 
out of the grass pollen season. 
STUDY DESIGN Case-control  Case-control  
STUDY POPULATION • 29 children (12 healthy subjects and 17 
asthmatics with good control). 
• Asthmatics divided into two groups; 
corticosteroids-naïve (n=9) and corticosteroids-
treated (n=8).  
• All asthmatics were atopic. 
 
 
• 21 grass pollen sensitised children (age 6 to 16 
years) with a seasonal allergic asthma. 
• 21 non-atopic healthy children age and sex 
matched with the asthmatics. 




AUTHORS Barreto et al, 200831 Baraldy et al, 199918 
INTERVENTION/ 
EXPOSURE  
1-week stay in a countryside sanatorium situated in 
a wooded area near the Tatra mountains at an altitude 
of 970 m. 
Followed up and monitored before (March), during 
(May), and after (November) the pollen season. 
OUTCOME 
MEASURES 
FeNO, lung function. FeNO, lung function. 
MEASURMENTS 
 
• On arrival, all subjects underwent a clinical 
examination and a history recorded of symptoms 
and therapy. Spirometry and FeNO 
measurements done on all subjects twice a day 
for the first 2 days and again at 8:00 am on day 
7.  
• All participants avoided food intake and physical 
exercise for at least 2 hours before testing. 
• All patients underwent physical examination, 
spirometry and measurement of FeNO on three 
occasions: before (March), during (May) and after 
the grass pollen season (November). On each 
occasion, measurements were performed in the 
afternoon. 
• The atmospheric pollen counts were condcuted 
throughout the year using a volumetric spore trap 




• Participants excluded from the study if 
unsatisfactory lung function maneuvers or 
respiratory symptoms developed during the 
weekly follow-up. 
and daily mean concentration recorded and 
expressed as pollen grains per m3 of air per 24 hrs. 
RESULTS • At baseline, the worst lung function observed 
among corticosteroid treated asthmatics and the 
highest FeNO values recorded in corticosteroid-
naive asthmatics.  
• The differences in FeNO at baseline between 
asthmatics versus healthy participants was 
significant only among corticosteroid-naive 
patients. 
• Differences in lung function between the groups 
remained unchanged at each session. 
• FeNO levels among corticosteroid-naive as well 
as treated asthmatics decreased over time and 
• ICS therapy was not altered through the pollen 
season for all subjects. 
• The mean value of FeNO before the grass pollen 
season (March) was (12.7 ± 5.1 ppb) and was 
significantly higher (p<0.001) when compared to 
healthy subjects (7.8 ± 2.7 ppb). 
• In the pollen season (May) there was a significant 
(p<0.001) two-fold increase in FeNO (21.4 ± 7.6 
ppb) with respect to pre-season baseline values. 
• After the season (November), FeNO returned to 
pre-seasonal values (12.8 ± 5.8 ppb). 




became statistically non-significant (vs healthy 
subjects) at the last session (day 7). 
• No intra-group differences were found between 
nocturnal and diurnal FeNO in all the groups. 
• No relationship was found between the changes in 
FeNO and changes in symptom scores.  
• No significant changes in lung function parameters 
during and after the pollen season. 
LIMITATIONS • Small sample size. 
• High altitude and climate may affect the results. 
• No mention of important confounders (passive 
smoking and diet). 
• There was no intra-group analysis to study the 
significance of the mean difference between day 
1 and day 7. 
• Small sample size. 
• No FeNO measurements taken for the control 
group during and after the pollen season. 
• No mention of important confounders (passive 
smoking and diet). 
 
 
CONCLUSION FeNO decreased a week after allergen avoidance at 
high altitude.  
• Natural allergen exposure during the grass season 
resulted in an increase in FeNO in asthmatic 
children which then returned to the level of the pre-
seasonal range after the season passed. 
  




Table 2: Epidemiological studies of serial longitudinal FeNO measurement among asthmatic children (continued) 
AUTHORS Adar et al, 201532 Holguin et al, 201533 
AIM OF STUDY To assess variability in FeNO in children in relation 
to exposures to diesel pollution from school buses. 
To assess the effects of traffic emissions on FeNO in 
children with and without asthma. 
STUDY DESIGN Case-control Case-control. 
STUDY POPULATION • 275 children riding on diesel school buses, with a 
mean age of 9.5 years.  
• 148 were asthmatics, and 127 were healthy 
subjects. 
• 200 children (age 6 to 12 years),  
• 50% had physician-diagnosed asthma, and 50% 
were healthy subjects. 
INTERVENTION/ 
EXPOSURE  
Children riding on school buses were monitored 
before, during and after the adoption of clean fuel 
technology, such as diesel oxidation catalysts 
(DOCs), closed crankcase ventilation systems 
(CCVs), ultralow-sulfur diesel (ULSD), and 
biodiesel. 
Children were monitored over a 4-month period to 
determine the effects of road and traffic densities, 
carbon and particulate matter on FeNO levels. 




AUTHORS Adar et al, 201532 Holguin et al, 201533 
OUTCOME 
MEASURES 
FeNO, lung function, air pollution levels on school 
buses. 




• Children were assessed an average of 6 times over 
4 years. 
• Lung function and FeNO were measured during 
monthly data collection sessions at the schools. 
• Fine and ultra-fine particles (UFP) were 
measured inside 188 buses during 597 commutes. 
• Children were assessed with spirometry, FeNO, and 
skin allergy testing bi-weekly over 4 months. 
• Daily respiratory health questionnaires were 
completed by parents. 
• Road-density (amount of road length in kilometers 
in each buffer) and traffic density (vehicle-km/h) 
within buffer areas around study schools and 
subject homes were measured. 
• Air pollution was measured at the schools as 
follows: 




o 48-hour average of less than 2.5 um (PM2.5) 
particulate matter and elemental carbon 
measurements. 
o Weekly NO2 measurements. 
RESULTS • Higher FeNO levels were observed among 
children with asthma, compared to healthy 
children.  
• Buses with ULSD were associated with reduction 
in UFP (-47%; 95% CI, -58 to -34%). 
• Buses with ULSD were associated with 16% 
lower FeNO, particularly in asthmatics.  
• Higher road density was associated with increased 
FeNO and reduced FEV1 in asthmatics. 
• No association was observed between fine 
particulate matter (PM2.5) or elemental carbon and 
FeNO. 
LIMITATIONS • Potential for important confounding by time 
(some technologies only used later in the study). 
• No mention of important confounders (atopy and 
diet). 
• Differences in measurement frequencies of PM2.5 
and NO2 could have affected results. 
• 48-hour PM2.5 measurements may not precisely 
capture daily pollution fluctuations. 




AUTHORS Adar et al, 201532 Holguin et al, 201533 
CONCLUSION Adoption of cleaner school bus diesel emission 
technologies reduced childrens’ exposure to fine and 
ultra-fine particles, which was associated with a 
decrease in FeNO levels, particularly in asthmatics.  
Increased traffic exposure leads to increased FeNO 
particularly in asthmatics. 
 
  




Table 2: Epidemiological studies of serial longitudinal FeNO measurement among asthmatic children (continued) 
AUTHORS Roberts et al, 200419 Spanier et al, 200420 Cutts et al. 201321 
AIM OF STUDY To evaluate the effect of pollen on 
FeNO in children with seasonal 
asthma.  
To evaluate seasonal and 
environmental effects on FeNO in 
tobacco-exposed children with 
asthma.  
To evaluate the variability in 
FeNO over a 10-month period in 
children with and without asthma.  
STUDY DESIGN Longitudinal study. Longitudinal study. Longitudinal study. 
STUDY POPULATION 
44 children (age 6 to 16 years) 
with seasonal allergic asthma. 
225 children (age 6 to 12 years) 
with physician-diagnosed asthma. 
• 178 primary school children, 
with a mean age of 9.6 years 
(SD = 1.3 years).  
• 47 were asthmatics, and 131 
were healthy subjects. 
INTERVENTION/ 
EXPOSURE 
Exposure to pollen during the 
pollen season 
Evaluated at baseline, 6, and 12 
months and assessed for 
environmental exposures. 
Monitored over a 10-month 
period and assessed for 
environmental exposures. 




AUTHORS Roberts et al, 200419 Spanier et al, 200420 Cutts et al. 201321 
OUTCOME 
MEASURES 
FeNO, lung function, daily 
asthma symptoms. 
FeNO, settled dust allergens 
(SDA), indoor airborne particles 
(IAP), allergen sensitsation, 
tobacco smoke exposure.  
FeNO, lung function, daily 
asthma symptoms questionnaire. 
MEASUREMENTS 
 
• Evaluated before the pollen 
season; then at regular 4-
weekly intervals throughout 
one pollen season. 
• All patients underwent 
physical examination, 
spirometry and measurement 
of FeNO.  
• Atmospheric pollen counts 
were taken throughout the 
• FeNO measured.  
• Dust mite, dog, cat and 
cockroach allergens measured 
with monoclonal ELISA. 
• Indoor particulate matter 
measured. 
• ImmunoCap for allergen 
sensitisation. 
• Tobacco smoke exposure 
measured with using a survey, 
FeNO measured at 2-month 
intervals, on between 4 and 6 
different occasions (851 
measurements) as follows:  
• 86 children measured on 6 
occasions; 
• 51 children measured on 4 
occasions. 
• 21 children measured on 4 
occasions. 




pollen season with a 7-day 
volumetric spore trap. 
biomarkers (hair and serum 
cotinine) and a nicotine 
dosimeter.  
RESULTS • There was a significant 
increase in median FeNO 
during the pollen season (9.2 
ppb) compared to before the 
pollen season (6.2 ppb) 
(p=0.002). 
• There was a significant 
relationship between 
standardized FeNO and pollen 
counts on the day of 
measurement (p<0.01). 
• No significant changes were 
seen in lung-function 
• Significant associations were 
seen between longitudinal 
change in FeNO and baseline 
FeNO. 
• Lowest and highest FeNO 
levels were seen in winter and 
autumn (fall), respectively 
(p=0.002). 
• Being atopic lead to increased 
FeNO levels. 
• Cat and dust mite allergen 
levels significantly increased 
FeNO. 
• Significant associations were 
seen between initial FeNO 
concentrations and future 
values. 
• FeNO increased during the 
pollen session (increase in log 
transformed FeNO 1.34 [95% 
CI 1.05-1.70]) and elevated 
also in those with mould at 
home during September–
October. 




parameters before or during 
the pollen season. 
• Airborne nicotine 
significantly decreased FeNO. 
• FeNO was not associated with 
passive smoking exposure 
when measured by biomarkers 
and reported smoking by 
parents. 
LIMITATIONS • Small sample size. 
• Absence of a control group of 
children without seasonal 
asthma. 
• No mention of important 
confounders (daily activities, 
and diet). 
 
• Absence of a control group of 
children not exposed to 
tobacco smoke. 
• Settled dust allergens were 
only measured at baseline.  
• Uneven numbers of 
measurements taken on 
different sample groups. 
• No mention of important 
confounders (daily activities, 
and diet). 




AUTHORS Roberts et al, 200419 Spanier et al, 200420 Cutts et al. 201321 
CONCLUSION Natural allergen exposure during 
the pollen season increased FeNO 
in asthmatic children. 
Environmental triggers, airborne 
nicotine, and baseline allergen 
sensitisation affected FeNO 
levels. 
Both baseline FeNO values and 
intervals between FeNO 
measurements were related to 
individual FeNO values, 











Table 3: Epidemiological studies and case reports of serial longitudinal FeNO measurement in adults  
Table 3A. Epidemiological studies among adults and working populations 
AUTHORS Hewitt et al, 200834 Van der Walt et al, 201611 Fowler et al, 200922 
AIM OF STUDY To assess whether serial FeNO 
measurements may detect 
exposure-related inflammation in 
laboratory animal workers 
To evaluate the association 
between FeNO and occupational 
exposures to spices. 
To assess whether exposure to 
common domestic allergens 
affects long-term FeNO 
measurements in adult asthmatics 
STUDY DESIGN Longitudinal study Cross-sectional study Longitudinal study 
STUDY POPULATION • Fifty laboratory animal 
workers in four research 
centers.  
• Each subject was exposed to 
laboratory animals to a 
minimum of two occasions 
• Permanent (n=139) and 
casual (n=11) workers in a 
spice mill (total n=150). 
• Mean employment duration 
of 6.9 years in the factory and 
3.2 years in the current job. 
• 165 subjects with asthma, 
measured at home, 82% of 
which were atopic, 18% of 
which were non-atopic.  
• Each subject was assessed 
twice, 4 years apart (mean = 
47 months). 




per week for six months or 
longer.  
• There was no exclusion based 
on clinical history. 
INTERVENTION/ 
EXPOSURE 
Exposure to laboratory animals in 
the workplace. 
Exposure to spices in the 
workplace. 
Exposure to mite, dog and cat 
allergens in the household. 
OUTCOME 
MEASURES 
Symptom questionnaire, peak 
expiratory flow measurements, 
lung function and FeNO. 
Immunological tests for common 
inhalants and occupational agents 
(garlic, chili pepper and wheat), 
spirometry and FeNO. 
Lung function, FeNO, and 
immunological tests for 




• Subjects were initially 
assessed on a Friday. 
• Subjects received instruction 
on the use of a peak flow 
meter and a symptom diary.  
Serial FeNO measurements were 
conducted as follows: 
• Baseline pre-shift on 
Monday. 
• Post 8 hour shift. 
Allergen exposure was measured 
using monoclonal ELISA. 
 




• Having avoided contact with 
laboratory animals over the 
weekend, they were assessed 
at the beginning and at the end 
of each working day from 
Monday to Friday of the 
following week. 
• Pre-shift test on the following 
Tuesday.  
Each subject underwent 2 
measurements, 4 years apart as 
follows: 
• All underwent spirometry and 
measurement of FeNO. 
• Allergic sensitisation was 
measured by skin-prick 
testing. 
 
RESULTS • Two of the 50 subjects had a 
positive specific IgE to one or 
more laboratory animal 
allergen (LAA). 
• Baseline FeNO were highest 
in two subjects sensitised to 
• The geometric mean of FeNO 
change across shift (15.43 
ppb) was very similar to the 
mean change across the 24-
hour period (15.84 ppb). 
• There was a mean 1.4-fold 
decrease in FeNO over the 4-
year period (p<0.001). 
 




LAA, having FeNO of 213.0 
ppb and 179.0 ppb.  
• Mean FeNO was (19.8 ± 20.1 
ppb) and (21.7 ± 20.8 ppb) in 




• Progressive increases in 
FeNO occurred only in one of 
the seropositive individuals 





• FeNO increase (>12%) across 
a 24-hour period was 
significantly associated 
(OR=3.77; CI 1.01-14.24) 
with exposures to higher spice 
dust particulate but no effect 
observed across the 8-hour 
work shift. 




AUTHORS • Hewitt et al, 2008
34 • Van der Walt et al, 201611 • Fowler et al, 200922 
LIMITATIONS • Small sample size.  
• Subjects were not all 
asthmatic. 
• No mention made of 
important confounders. 
However, mention was made 
of the workplace protection 
not being uniform. 
• No comparable unexposed 
group. 
• Short follow-up duration 
• The level of exposure was not 
measured at the second visit. 
• Possibilities for selection bias  
• No control group of healthy 
adults. 
• Possibility of important 
confounders (high doses of 
ICS among all participants).  
CONCLUSION Serial FeNO could assist in 
monitoring patients sensitised to 
occupational allergens. However, 
its value decreases if the patient is 
also sensitised and exposed to 
FeNO level increase was more 
pronounced 24 hours after the 
exposure to spice dust particulate. 
Long-term exposure to dust mite 
and dog allergens in the home 
caused significant changes in 
bronchial hyperresponsiveness, 
but not necessarily in FeNO 
levels of asthmatic adults. 




non-occupational allergens which 








Table 3B. Case reports of adult working population      
AUTHORS Merget et al, 201435 Merget et al, 201636 
AIM OF STUDY To assess the practicality of serial measurements of 
FeNO as diagnostic tool for occupational asthma. 
A case report of triticale (wheat/rye) allergy in a farmer. 
STUDY DESIGN Case study  Case study  
STUDY POPULATION 51-year-old male smoker working as a baker since 
adolescence who complained of shortness of breath 
and cough. 
29-year-old farmer with hay fever and atopic dermatitis 
since adolescence diagnosed with work-related asthma. 
INTERVENTION Avoidance of exposure for 2 weeks. Avoidance of exposure for 2 weeks. 
OUTCOME 
MEASURES 
Change of FeNO level over time. Change of FeNO level over time. 
MEASURMENTS 
 
FeNO measurement was performed once daily over 
a 2 weeks holiday period and thereafter over 3 
weeks of working days. 
• FeNO measurement was performed once daily 
during a working week and thereafter over a two-
week holiday period.  




• Measurements were done in the evenings, (after 
work) in the working period. 
RESULTS FeNO decreased to the normal level soon after the 
start of the holiday period and showed a clear 
increase after resuming work. 
FeNO decreased gradually over time soon after the start 
of the holiday period. 
LIMITATIONS Case study design Case study design 
CONCLUSION FeNO decreased over 2 weeks of allergen and 
irritants avoidance and showed a clear increase over 
the working day period 
FeNO decreased over 2 weeks of allergen avoidance in 
a patient with occupational asthma to triticale 




Exposure to specific sensitising agent  
All the studies identified focused mainly on serial FeNO changes with exposure to high 
molecular weight (HMW) agents. However, it has been previously reported that the increase 
in FeNO after specific inhalation challenge tests in patients with suspected occupational asthma 
is more strongly associated with exposure to HMW than low molecular weight (LMW) agents, 
the former known to be commonly associated with allergic IgE-mediated airway 
inflammation.12  
Other exposure characteristics  
While it could be hypothesised that exposure duration, exposure concentration or cumulative 
exposure may play a role in determining serial changes of FeNO in population-based studies, 
we were unable to identify many studies that evaluated these potential relationships. However, 
Lemiere et al12 evaluated this association between serial changes in FeNO and the duration of 
exposure to the potential allergen during SIC tests and the association was not found to be 
significant (OR = 0.99, 95% CI 0.9-1.0). Although the overall association between the overall 
change in FeNO and the concentration of allergens exposure was not statistically significant, 
Van der Walt et al11 found a significant association between workers exposed to high 
concentrations of spices and >12% increase in FeNO in their mill workers (OR = 3.77, 95% CI 
1.01-14.24). Furthermore, a positive correlation has also been demonstrated between the degree 
of FeNO reduction after HDM avoidance and baseline HDM allergen levels measured in the 
beds of subjects (r = 0.618, p = 0.026) by Piacentini et al in their asthmatic children.24  
 




Air pollution  
Exposure to air pollutants could contribute to changing FeNO levels, especially in busy large 
cities. Adar et al32 found that reducing ultrafine particles by adoption of clean fuel technology 
in school buses leaded to a reduction in FeNO among bus riders by 16%. This association was 
more prominent in asthmatic children. Moreover, Holguin et al33 found that exposure to higher 
road density was associated with a significant increase in FeNO in asthmatic children and a 
non-significant increase in healthy children. Furthermore, both studies found no association 
between FeNO and exposure to PM2.5 particulates. This suggests that PM2.5 may not be useful 
in studying the association between FeNO and air pollution in children. 
HOST ASSOCIATED FACTORS 
Asthma education  
The effect of asthma education programs on asthma control has been evaluated through several 
studies of children. Kaminsky et al27 evaluated 25 asthmatic children, 21 on inhaled 
corticosteroids (ICS), participating in a one-week camp organised with asthma education 
programs. The overall mean FeNO dropped by 45% (p<0.001) at the end of the week. This 
decline could be attributed to ICS, which was found to reduce FeNO in asthmatics in a dose-
dependent manner.39 40 However, three of the four children who were not on ICS also 
demonstrated a decrease in FeNO at the end of the camp. The authors indicate that it is also 
possible that the changes in FeNO could have been due to other additional factors such as 
allergen avoidance or absence of anxiety triggers in the home.41 42 Furthermore, Kaminsky et 
al did not specify the asthma control status of the subjects that were evaluated. It is possible 
that a large proportion were non-compliant or under-treated so that the change in FeNO could 
have been due to improved asthma control. This was evident in the study by Barreto et al31 who 
studied asthmatic children with good asthma control in a sanatorium for one week, which was 




accompanied with an asthma education program. The study reported that the mean baseline 
FeNO in asthmatics on ICS did not differ from the healthy subjects nor did it differ over the 
entire week. In contrast, asthmatics not on ICS had a higher FeNO baseline (p < 0.005) 
compared to the healthy subjects and showed a progressive decrease over the week until the 
difference reached non-significance (p = 0.057). This is further explained by the study of 
Jatakanon et al43 that demonstrated a plateau of exhaled FeNO in response to higher doses of 
ICS.  
Asthma education programs have also been evaluated in adults in domestic and occupational 
settings. Dressel et al29 evaluated FeNO after a one-day asthma education program in 81 animal 
farmers with occupational asthma that were sensitised to cow dander and storage mites. The 
overall mean FeNO decreased by 9% (p = 0.042) after 4-6 weeks after the program and by 18% 
(p = 0.003) among those with a baseline FeNO of >35ppb. There were 43 subjects in this study 
who were re-evaluated after one year to assess long-term changes in FeNO after the asthma 
education program.30 The mean FeNO decreased by 21% (p = 0.001) in the intervention group. 
While measures to reduce exposure to the allergens, such as use of personal protective 
equipment, changing work clothes before going home and washing hair before going to bed, 
were major contributors to this reduction in FeNO in both studies, compliance to medication 
was also cited as an additional contributor to these positive findings. This was evident also in 
the study by Saito et al28, which provided asthma education program to 50 asthmatics with poor 
adherence to medication. The program was aimed at increasing compliance to medications and 
to improve the inhalation technique. The study reported a significant decrease in the overall 
mean FeNO after a year of follow-up (visits at 3, 6, 12 months from the baseline) in stable 
patients (n = 42) even though asthma medication was stepped down in 33% of the subjects. 
However, there was a non-significant reduction in FeNO in 16 subjects who were initially 




unstable and required an increase in ICS dosage or additional asthma medication during the 
course of the study. 
Atopy 
It is well known that FeNO levels are higher among atopic subjects irrespective of the domestic 
or occupational exposures.3-5 These findings were also reported by Van der Walt et al11 in their 
study of spice mill workers. However, strong associations between atopic status and 
longitudinal changes in FeNO have not been studied in detail. Changes in FeNO appear to be 
independent of the atopic status.26 34 Spanier et al20 found that the seasonal variation of FeNO 
did not differ between the atopic and non-atopic subjects. Moreover, Lemiere et al12 reported 
a non-significant positive association between changes in FeNO and atopy status (OR 2.0, 95% 
CI 0.5-7.5) in their study of FeNO measured after SIC to occupational agents in patients with 
occupational asthma. 
Smoking status  
It is well known that smoking is associated with a decreased baseline FeNO in subjects.3-5 
However, strong associations between smoking status and longitudinal changes in FeNO have 
not been studied in detail. Lemiere et al12 in their study of patients with occupational asthma 
found a non-significant positive association between FeNO changes and negative smoking 
status (OR 1.5, 95% CI 0.5-4.3) after SIC to occupational agents in patients with occupational 
asthma. 
In children, passive smoking may have an effect on longitudinal changes in FeNO. Spanier et 
al20 found that exposure to passive smoking measured by a nicotine dosimeter lead to a 
significant decrease in FeNO. However, this association disappeared when the exposure 
reported by the parent’s survey was used suggesting possible recall bias. 
 




Baseline pulmonary function and fractional exhaled nitric oxide  
While the relationship between baseline FeNO and Forced Expiratory Volume (FEV1) has been 
evaluated in a number of studies, studies evaluating the association between baseline FEV1 and 
the longitudinal change in FeNO are scanty. Peroni et al25 did not find a correlation between 
FEV1 and longitudinal changes in FeNO in their study. Lemiere et al
12 also reported a non-
significant association between changes in FeNO post SIC and baseline FEV1, nor was this 
association present with a maximum fall in FEV1 after SIC. However, Saito et al
28 found a 
significant correlation between change in FeNO and the change in FEV1 in the first 3 months 
of their study, which remained significant until the end of the study after 12 months of baseline. 
While it could be hypothesised that baseline FeNO may be a good indicator of the magnitude 
of future change in serial FeNO, studies in this area that evaluated this potential relationship 
were scant. In children, Spanier et al20 and Cutts et al21 found a significant association between 
baseline FeNO and longitudinal changes in FeNO. However, Lemiere et al12 were unable to 
demonstrate an association between baseline FeNO (>25ppb) and change in FeNO post SIC in 
an adult group. 
CONCLUSION 
In conclusion, avoiding the exposure of the offending agents has been shown to decrease the 
airway inflammation as evaluated by FeNO which can be regarded as an important marker of 
airway inflammation in asthma among both symptomatic and asymptomatic subjects. While 
the predictors of baseline FeNO levels have been evaluated in several clinical and population-
based studies, the evidence for various factors associated with longitudinal changes in FeNO 
need further investigation. These include smoking, atopy, baseline FeNO, baseline FEV1 and 
exposure characteristics (agent and dose), which need further evaluation, especially in 




occupational settings. Modulating exposures through the introduction of intervention to reduce 
allergen exposures can be used to study these changes in epidemiological studies.  
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KEY MESSAGES AND KEY WORDS 
 
Key messages 
What is already known about this subject? 
The reduction of workplace exposure to airborne allergen can improve the health outcomes of 
the exposed workers. 
 
What are the new findings? 
Workplace interventions that aim at reducing exposure to occupational sensitisers, resulted in 
a significant decline (>10%) in fractional exhaled nitric oxide among those with pre-existing 
upper airway involvement and work-related ocular-nasal symptoms. 
 
How might this impact on policy or clinical practice in the foreseeable future? 
Fractional exhaled nitric oxide could be a useful tool to monitor the effectiveness of workplace 
interventions that aim at reducing exposure to occupational sensitisers, particularly among 
those with pre-existing upper airway involvement and work-related ocular-nasal symptoms. 
 
Key words 
work-related asthma; allergic sensitisation, exposure reduction, workplace interventions. 
  





Aim: To assess the health impact of an intervention in supermarket bakeries using fractional 
exhaled nitric oxide and other clinical endpoints for baker’s allergy and asthma after a one-
year follow-up period.  
Methods: A field randomised controlled trial of 31 bakeries initially assigned to one of two 
intervention groups (bakery mixer lid and training) (n=244) and a control group (n=93). Health 
data prior to and after the intervention included a modified ECRHS questionnaire; Phadiatop 
® and serum specific IgE to cereal flours (wheat, rye, alpha-amylase); and FeNO performed 
during the work shift using NIOX MINO®. The data of the two intervention groups was 
combined into one intervention group for the analysis. Data was analysed using STATA 
(version 12). 
Results:  The two groups were comparable with regard to age (32-33 years), proportion of 
females (55%-57%) and smoking status (38%-40%). The intervention group had a significantly 
higher prevalence of workers with atopy (42%, p=0.025), work-related chest symptoms (25%, 
p=0.044) and sensitisation to cereal flour allergens (35%, p=0.042) at baseline than the control 
group (25%, 15%, 23% respectively). At one year of follow-up, the incidence and level of 
decline of work-related ocular-nasal and chest symptoms, sensitisation status and elevated FeNO 
(FeNO >25ppb) was similar in the two groups. The mean difference in FeNO was similar across 
the two groups (2.2ppb vs 1.7ppb, p=0.860). However, when stratifying according to baseline 
FeNO >25ppb, the FeNO decline was greater in the intervention group (16.9 ppb) than in the 
control group (7.7ppb), although not statistically significant (p=0.237). Multivariate logistic 
regression models (adjusting for smoking, baseline sensitisation to cereal flour, baseline FeNO 
>25ppb) did not demonstrate an appreciable decline in FeNO (>10%) in the intervention 
compared to the control group. However, stratification according to the presence of work-




related ocular-nasal symptoms at baseline demonstrated a significant decline (>10%) in FeNO 
in the intervention group compared to the control group (OR=3.73, CI: 1.22-11.42). 
Conclusion: This study demonstrates some evidence of an intervention effect on exhaled nitric 
oxide (FeNO) one year after the intervention, particularly among bakers reporting work-related 
ocular-nasal symptoms at baseline. The lack of a demonstrably stronger effect on other clinical 
endpoints can be attributable to the short follow-up period.  





Work-related asthma accounts for at least 15% of adult asthma, resulting in significant 
morbidity and disability.1 2 Various strategies have been developed in attempts to reduce the 
burden of the disease and improve the prognosis of workers with occupational asthma. One of 
the approaches which has been found to be beneficial is the reduction of exposure to the 
offending sensitiser.3 4  However, studies that have evaluated the effectiveness of interventions 
aimed at reducing exposure to occupational sensitisers are scant.3 5 Only two studies among 
these reported objective measurements of the level of exposures encountered.3 6 7 Furthermore, 
most of the studies have reported on asthma symptoms, lung function or non-specific bronchial 
hyperactivity (NSBH) in evaluating the outcome of exposure reduction measures. Few studies 
have utilised the presence of airway inflammation as an objective outcome measure in 
assessing the effectiveness of exposure reduction in occupational settings. 
Fractional exhaled nitric oxide (FeNO) can be regarded as an important marker of airway 
inflammation in asthma among both symptomatic and asymptomatic subjects. Whereas the 
predictors of baseline FeNO levels have been evaluated in several clinical and population-
based studies, the evidence for various factors associated with longitudinal changes in FeNO 
need further investigation.8 However, ongoing exposure and avoidance of exposure to 
occupational airborne allergens were the main determinants of longitudinal change in FeNO.8 
In an earlier phase of this study, the effectiveness of a multi-faceted intervention to reduce 
exposure to flour dust in supermarket bakeries with high flour dust levels and a population with 
a high prevalence (13%) of baker’s asthma9 was evaluated.10 The specially designed 
intervention strategy was found to be extremely effective in reducing airborne dust and allergen 
levels by 50%-80%.11 The aim of the current study was to assess the health impact of these 




intervention using FeNO and other clinical endpoints for baker’s allergy and asthma one year 
after the intervention. 
METHODS 
Study design and population  
This study of a group field randomised controlled trial involved the analysis of data that was 
collected in 2011 as a part of a larger study started in 2003.10 The original study identified 31 
bakeries in the Western Cape province of South Africa as the potential population for the study. 
Out of these bakeries, 18 were randomly assigned to two intervention groups and one control 
group, taking into consideration the size of the bakery and number of workers in each bakery 
(figure 1). Two intervention strategies were developed, using a bakery mixer lid and training, 
through a focused group discussion that involved bakery workers, managers and engineers.11 
An assessment for baseline environmental exposure was initially performed using full-shift 
personal samples to measure the level of exposure to flour dust in different job categories in 
the bakeries.10 This was followed by a baseline health survey of 424 participants investigating 
chest  symptoms, ocular-nasal symptoms and work-related symptoms using a short 
questionnaire (appendix 2). Furthermore, serum specific IgE to wheat, rye and α-amylase as 
well as FeNO were assessed prior to implementing the intervention.12 One year after 
implementation, the effectiveness of the intervention was assessed using flour dust levels.11 
Later, a cross sectional survey was administered to 361workers among whom 337 were from 
the original cohort that participated in earlier phases. In this phase, data was collected on work-
related symptoms using the modified the European Community Respiratory Health Survey 
(ECRHS) questionnaire (appendix 3),13 specific IgE to wheat, rye and fungal amylase and 




FeNO. In the current study, the complete data collected from the 337 workers (244 participants 
from the two intervention groups and 93 participants from the control group) was analysed.  
 
Figure 1: Flow diagram illustrating intervention study design and bakeries assessed pre-and 
post-intervention. 




The data of the two intervention groups (bakery mixer lid group and training group) was 
combined into one intervention group for the analysis. Eighty-seven workers were not traceable 
for further evaluation for various reasons (e.g. store closure). However, the current cohort (337 
workers) adequately represented different job categories found in the bakery environment. The 
study received ethical approval from the University of Cape Town, South Africa (appendix 6). 
Health outcome assessment  
Skin prick tests 
The data of skin prick tests (SPTs) was obtained from a previous sub-study.9 ALK-Abello´ 
A/S, Horsholm, Denmark was used to test for common local allergens. Reading of the tests 
was done 15 minutes after testing and areas of the wheal were traced on a clear tape. A wheal 
of ≥3 mm more than the negative control was considered positive. Atopy was defined as the 
presence of a positive SPT to one or more common aeroallergens. 
Respiratory questionnaire 
A standard questionnaire designed based on the protocol for the European Community 
Respiratory Health Survey (ECRHS)13 was administered to the participants (appendix 3) in the 
follow-up study. It gathered information on acute and chronic respiratory and ocular nasal 
symptoms and work-relatedness of these symptoms. It also covered information related to 
current and previous employment, levels of exposure to flour dust and tobacco smoke. The 
modified questionnaire was administered in either English or Afrikaans. 
Serum immunological tests 
Blood samples were obtained from the participants for serum-specific immunoglobulin IgE. 
Sera were tested to determine the presence of atopy using Phadiatop® test (ImmunoCAP 100 
System; Phadia, Uppsala, Sweden). The sera were also tested for specific IgE to flour dust 
allergens such as wheat (f4), rye (f5) and fungal a-amylase (k87) using fluorescence enzyme 




immunoassay (CAP-FEIA) according to the manufacturer’s instructions (Phadia). Results were 
treated as a continuous or binary variable in which ImmunoCAP ≥ 0.35 kU/L) was considered 
positive. 
Fractional exhaled nitric oxide determination  
A hand-held portable nitric oxide sampling device (NIOX MINO) was used to determine FeNO 
during the work shift. It was performed in a room distant from the bakery area during the work 
shift throughout the working week, according to American Thoracic Society (ATS)/European 
Respiratory Society (ERS) recommendations.14 15 The testing of workers had no particular 
variation with regard to time of testing for the different jobs. The average of three technically 
adequate FeNO measurements was determined. Workers were instructed to abstain from 
smoking, eating or drinking at least one hour before the test. This was confirmed prior to 
testing, and those who did not follow the instructions were tested at a later stage after ensuring 
their full compliance with these instructions. Levels of FeNO were treated either continuous 
variable (log-transformed), or binary variable FeNO >25ppb and FeNO>50ppb. A 10% decline or 
more in FeNO was considered significant reduction in airway inflammation post intervention. 
Statistical analysis  
Data was analysed using STATA V.12 computer software (StataCorp, College Station, Texas, 
USA). Data is presented as proportions, means (geometric where appropriate) or median and 
the corresponding standard deviation (SD) or interquartile range (IQR). Chi-square test and an 
independent t-test (or Fisher’s exact test and Wilcoxon sum rank test where appropriate) were 
used to compare groups at baseline as well as to determine the effect of intervention on the 
incidence and decline of allergic and respiratory health outcomes at one-year follow-up. 
Univariate linear regression was used to explore the determinants of longitudinal change in 
FeNO. Multivariate regression analysis was used to determine predictors of a 10% or more 




decline in FeNO using the intervention and adjusting for other confounders such as current 
smoking, baseline FeNO>25ppb and sensitisation to cereal flour allergens. Further subgroup 
multivariate regression analysis stratified by the presence of work-related ocular nasal 
symptoms was used to assess effect modification. A two-tailed p-value of <0.05 was considered 
to be statistically significant. 
RESULTS 
The general characteristics of the 337 participants are presented in Table 1. The two groups 
were comparable with regard to age (32-33 years), proportion of females (55%-57%) and 
smoking status (38%-40%). The intervention group had a significantly higher prevalence of 
workers with atopy compared to the control group (42%, 25% p=0.025). The intervention 
group had a significantly higher baseline prevalence of workers with work-related chest 
symptoms (25%, p=0.044) and sensitisation to cereal flour allergens (35%, p=0.042) at baseline 
than the control group (15% and 23% respectively). No significant differences were found for 
other allergic and respiratory health outcomes as shown in Table 1. 
Table 1: Baseline characteristics of supermarket bakery workers 
Predictor 
Intervention group 
n                  N       % 
Control group 




Age, median (IQR)  33 (12) 244 - 32 (11) 93 - 0.579 
Gender (female)  139 244 57 51 93 55 0.725 
Weight, median (IQR) 74.5 (29) 244 - 74 (28) 93 - 0.528 
Height, mean±SD# 165±8.2 155 - 166±9.3 56 - 0.594 
BMI, median (IQR) # 27.8 (9.5) 155 - 28.7 (10.6) 56 - 0.583 
Current smoker  93 244 38 37 93 40 0.695 




Atopy (skin prick test) # 65 155 42 14 56 25 0.025 
Current steroid use for 
asthma and/or rhinitis 
8 244 3 1 93 1 0.453* 
Current employment status 
(Permanent) 
214 244 88 83 93 89 0.696 
Current job with high 
exposure 
161 222 73 54 83 65 0.203 
Duration of employment 
in the bakery industry, 
median (IQR) 
7 (7) 241 - 7 (10) 89 - 0.869 
Ocular-nasal symptoms   83  244 34 31 93 33 0.906 
Work-related ocular-nasal 
symptoms  
92  241 38 34 93 37 0.785 
Medication use for ocular-
nasal symptoms   
15 244 6 7 93 8 0.647 
Asthma attack in the last 
12 months  
15  244 6 7 93 8 0.647 
Work-related chest 
symptoms   
61  241 25 14 93 15 0.044 
Medication use for asthma   12  244 5 3 93 3 0.768* 
Specific IgE ≥ 0.35 kU/L 
       
− Wheat  66  200 33 18 80 23 0.083 
− Rye 58  200 29 17 80 21 0.186 
− α-amylase  2  200 1 1 80 1 1.0* 




70  200 35 18 80 23 0.042 





































* Fisher’s exact test 
# Data obtained from a previous sub-study; Baatjies et al.9 
 
At one-year of follow-up, the incidence and level of decline of work-related ocular-nasal and 
chest symptoms, sensitisation status and elevated FeNO was very similar in both groups as 
shown in Tables 2 and 3. The mean difference in FeNO was similar across the two groups 
(2.2ppb vs 1.7ppb, p=0.860). However, when stratifying according to baseline FeNO >25ppb, 
the FeNO decline was greater in the intervention group (16.9 ppb) compared to the control 
group (7.7ppb), but not statistically significant (p=0.237) (Table 3). This was also evident when 
stratifying according to baseline FeNO >50ppb. FeNO decline approached borderline 
significance as the proportional level of decline increased when baseline FeNO>25ppb such 
that 49% of the intervention group and 28% of the control group experienced a 40% decline 
(p=0.07). 
Table 2: Incidence of allergic and respiratory health outcomes in supermarket bakery workers 
at one-year follow-up 
Predictor Intervention group Control group Chi-square 
 n N# % n N# % p-value 
Ocular-nasal symptoms  41 161 25 15 62 24 0.844 
Work-related ocular-nasal 
symptoms  
41 149 28 15 59 25 0.759 
Medication use for ocular-
nasal symptoms   
38 229 17 18 86 21 0.370 
Asthma attack in the last 12 
months  
4 229 2 1 86 1 1.0* 






29 180 16 18 79 23 0.199 
Medication use for asthma 17 232 7 5 90 6 0.572 
Specific IgE ≥ 0.35 kU/L 
       
− Wheat  11 134 8 2 60 3 0.351 
− Rye 12 141 9 3 61 5 0.560 
Specific IgE ≥ 0.35 kU/L 
       
− α-amylase  2 196 1 2 77 3 0.316 
− Any one of the 
cereal flour allergens 
 
14 130 11 3 60 5 0.195 
FeNO (ppb) 
       
















# Population at risk free of the adverse health outcome of interest at baseline 
 * Fisher’s exact test 
 
Table 3: Relative decline in allergic and respiratory health outcomes in supermarket bakery 
workers assessed at one year follow up 
Predictor 
Intervention group Control group Chi-
square 
 n N# % n N# % p-value 
Work-related ocular-nasal symptoms  37 92 40 17 34 50 0.325 
Medication use for ocular-nasal 
symptoms   
4 15 27 3 7 43 0.630* 
Asthma attack in the last 12 months  6 10 60 2 5 40 0.608* 
Work-related chest symptoms  24 61 39 5 14 36 0.801 
Medication use for asthma 3 12 25 0 3 0 1.0* 
Specific IgE change, median (IQR)          
− Wheat  0.01 (0.06) 198  0.01 (0.05) 78  0.011 




− Rye 0.01 (0.06) 198  0.01 (0.05) 78  0.097 
− α-amylase  0 (0.01) 198  0 (0.01) 78  0.311 
Specific IgE ≥ 0.35 kU/L 
       
− Wheat  9 64 14 0 18 0 0.195* 
− Rye 8 57 14 1 17 6 0.675* 
− α-amylase  0 2 0 0 1 0 - 
− Any one of the cereal flour 
allergens 
14 68 21 1 18 6 0.177* 
FeNO change, mean±SD# 2.2±23.0 244  1.7±14.5 91  0.857 
Proportion decline in FeNO          
− 10% decline  125 244 51 40 91 43 0.177 
− 20% decline 100 244 41 33 91 35 0.356 
− 30% decline 75 244 31 24 91 26 0.374 
− 40% decline 52 244 21 15 91 16 0.287 
FeNO change if baseline>25ppb, 
mean±SD# 
16.9±35.2 63  7.7±24.2 25  0.237 
Proportion decline in FeNO if baseline 
>25ppb 
         
− 10% decline 44 63 70 16 25 64 0.596 
− 20% decline  41 63 65 13 25 52 0.256 
− 30% decline  36 63 57 9 25 36 0.074 
− 40% decline  31 63 49 7 25 28 0.070 
FeNO change if baseline >50ppb, 
mean±SD 
26.1±45.5 31  11.5±39.3 8  0.413 
Proportion decline in FeNO if 
baseline>50ppb 
         
− 10% decline 22 31 71 5 8 63 0.682* 
− 20% decline  22 31 71 4 8 50 0.402* 
− 30% decline 21 31 68 3 8 38 0.220* 
− 40% decline 19 31 61 3 8 38 0.261* 
* Fisher’s exact test 
# Wilcoxon sum rank test 
 
In the univariate linear regression analysis (Table 4), ocular-nasal symptoms and baseline 
FeNO were significant determinants of the percentage (%) longitudinal change in FeNO. 




Current smoking status and work-related ocular nasal symptoms were borderline (p = 0.088 
for both predictors). However, belonging to the intervention group, atopy, current use of 
steroids (for rhinitis/asthma) and duration of employment in the bakery industry were not 
significant predictors. Multivariate logistic regression models adjusting for smoking, baseline 
sensitisation to cereal flour and baseline FeNO >25ppb), did not demonstrate an appreciable 
decline in FeNO (>10%) experienced by the intervention compared to the control group (Table 
5). However, stratification according to the presence of work-related ocular-nasal symptoms at 
baseline demonstrated a significant decline (>10%) in FeNO in the intervention group 
compared to the control group (OR=3.73, CI: 1.22-11.42).  
Table 4: Determinants of percentage (%) longitudinal change in fractional exhaled nitric oxide 
among supermarket bakery workers in univariate linear regression models 
Predictor  Estimate (β1) p-value 
Gender  -0.4159 0.970 
Age  0.5874 0.394 
Weight -0.0928 0.734 
Height -12.5942 0.885 
BMI -0.2321 0.803 
Current smoker  18.8604 0.088 
Current alcohol drinking  -0.7997 0.370 
Current steroid use for asthma and/or rhinitis 5.3648 0.866 
Ocular-nasal symptoms  22.8486 0.045 
Work-related ocular-nasal symptoms    18.9564 0.088 
Current job with high exposure -2.0081 0.871 
Duration of employment in the bakery industry 0.8152 0.344 
Intervention vs control group 13.2170 0.275 
Atopy (skin prick test)  -19.8812 0.192 




Specific IgE to wheat -0.1696 0.751 
Specific IgE to wheat ≥ 0.35 kU/L 15.9971 0.232 
Specific IgE to rye -0.0117 0.972 
Specific IgE to rye ≥ 0.35 kU/L -0.4926 0.972 
Specific IgE to α-amylase -7.0740 0.185 
Specific IgE to α-amylase ≥ 0.35 kU/L -81.3346 0.172 
Specific IgE to any one of the cereal flour allergens ≥ 0.35kU/L 15.9472 0.227 















Table 5: Determinants of 10% or greater decline in FeNO among supermarket bakery workers in multivariate models 
Predictor Crude odds ratio Bakers with work-related 
ocular-nasal symptoms 
Bakers without work-related ocular-
nasal symptoms 










OR 95% Confidence 
Interval (CI) 
p-value 
Intervention vs Control Group  1.617 0.930 - 2.810 0.088 3.732 1.219 - 11.420 0.021 1.617 0.559 - 2.249 0.747 
Current smoker 0.921 0.557 - 1.523 0.749 0.997 0.416 - 2.389 0.995 1.001 0.522 - 1.923 0.996 
Specific IgE to any one of the 
cereal flour allergens ≥ 0.35 kU/L 
0.450 0.250 - 0.810 0.008 0.432 0.159 - 1.173 0.099 0.686 0.307 - 1.531 0.357 
Baseline FeNO>25ppb 3.571 1.936 - 6.587 <0.001 5.033 1.789 - 14.159 0.002 3.017 1.346 - 6.766 0.007 
 
 





This study is one of the few prospective field randomised control trials, and the first trial in 
bakers, that evaluated the long-term health outcomes of implementing an intervention at the 
workplace with the aim of reducing the incidence of occupational allergy and asthma. It is also 
one of the few studies that evaluated the predictors of longitudinal decline in FeNO. The overall 
findings of this study demonstrate that workplace interventions that aimed at reducing exposure 
to flour dust allergens can contribute towards suppression of allergic airway inflammation in 
exposed workers. This effect was more evident in workers with pre-existing moderate to high 
airway inflammation (FeNO>25 ppb) and ocular-nasal symptoms.  
The study, however, could not demonstrate significant differences in the incidence of asthma 
symptoms, ocular-nasal symptoms or medication use. This was probably due to the dilution 
effect on dust exposure as reported previously by Baatjies et al.11 Managers who were 
transferred to bakeries in the control group incorporated some elements of the intervention in 
their new bakeries. This resulted in dust exposures in the intervention group and the control 
group being very similar post intervention (GM 0.39 vs 0.44 mg/m3).11 
Aside from the dilution effect, the findings of this study demonstrate that persistent exposure 
to low level of airborne allergens can result in developing or worsening of asthma and ocular-
nasal symptoms as has been reported previously.16 Also, these findings were similar to the 
overall findings of previous studies on the health outcomes following removal from exposure 
to airborne allergens.3 6 17 A Cochrane systematic review3 identified only one  prospective 
controlled before-and-after study that evaluated the health outcomes of a workplace 
intervention aimed at reducing exposure to airborne allergen in farmers.6 The authors reported 
a significant decline in respiratory symptoms in the intervention group 4-6 weeks after a one 
day educational training compared to its baseline. However, the difference between the 




intervention group and the control group was not significant (Risk ratio 7.62, 95% CI 0.47-
124.22).3 6 Furthermore, Vandenplas et al17 reported that only 17.6% of workers recovered fully 
after reduction of exposure, 60.1% showed improvement but 20.6% of subjects became worse 
after exposure reduction. By comparison, the current study demonstrated 39% of workers with 
a decline in work-related chest symptoms and 16% with new onset of work-related chest 
symptoms. Moreover, de Groene et al3 reported that only 24.8% of participants reported 
absence of asthma symptoms after reduction of the exposure. In addition, Munoz et al18 
reported that the asthma control questionnaire (ACQ) scores were very similar among those 
workers who avoided and those with continued exposure to airborne allergens.  
The short duration of follow-up may also have contributed to the marginal findings in 
sensitisation and symptoms observed in this study. The participants were assessed only one 
year after implementing the intervention, which may have been insufficient to demonstrate a 
significant difference between the two groups. Malo and Ghezzo19 reported that the maximum 
level of improvement of non-specific bronchial hyperresponsiveness (NSBH) was observed at 
2.5-5 years post cessation of exposure. Furthermore, Perfetti et al20 showed that NSBH 
improved in 48% of subjects evaluated only after 5 years of  exposure cessation, whereas only 
19% of workers evaluated at less than 5 years showed improvement. This duration before 
symptom improvement could be explained by the presence of allergen specific IgE,21 which 
can be detected in the sera from a few months to several years after cessation of exposure.22–25 
Previous studies have shown that the half-life of specific IgE to anhydrides, snow crab and  
detergent enzymes allergens were reported as 12, 20, and 21 months respectively after 
decreasing the exposure levels of these allergens.24–26 In this study, the presence of flour 
specific IgE could explain the marginal findings in sensitisation and symptoms observed in this 
study. Despite the effectiveness of the intervention in reducing the exposure in the intervention 
group, the participants in this group may have still been exposed since levels ranging between 




0.01–3.27 mg/m3 of inhalable flour dust were still found despite the overall reduction in dust 
levels from baseline. This low-level dust exposure may have contributed towards persistence 
of flour specific IgE and respiratory symptoms. Future studies could investigate the half-life of 
flour dust allergens and their utility in predicting allergic symptoms. 
 
The results of this study suggest that airway inflammation, measured by FeNO, can be 
suppressed by reducing exposure to airborne allergens. Although the difference in FeNO 
between the two groups following the intervention was not significant (p=0.24), the FeNO 
decline (among those with baseline FeNO >25ppb) was greater in the intervention group 
(mean=16.9ppb) compared to the control group (mean=7.7ppb). Moreover, apart from both 
groups having similar allergen exposures, the incidence of sensitisation was also similar. This 
may explain the non-significant difference in the FeNO decline in both groups since FeNO 
levels  correlate with the level of allergen specific IgE.12 27 Although the effect of allergen 
avoidance on FeNO in paediatric studies has been inconsistent,8 a demonstrable association 
has been reported in the occupational setting.  Dressel et al6 demonstrated a significant decline 
in FeNO in the intervention group from its baseline after implementing a workplace 
intervention. However, the difference between the intervention and control groups was not 
statistically significant. Moreover, two case reports by Merget et al28 29 of a baker and a farmer 
sensitised to wheat, rye and triticale, demonstrated a decrease in FeNO after complete 
avoidance of the potential allergens for two weeks. However, there was no objective 
measurement of the exposures before and after the intervention in these studies. In the current 
study, the effect of occupational intervention on FeNO decline was more prominent in workers 
with FeNO >25ppb as demonstrated by a strong association observed between a ≥10% decline 
in FeNO and baseline FeNO >25ppb (OR=3.610, 95%CI: 1.964-6.637). 




Various approaches have been used to assess the longitudinal changes in FeNO over time. A 
decline of 10% in FeNO has been suggested previously for tapering oral corticosteroid in 
patients with severe asthma.30 Based on the data and using this as a cutoff to evaluate the 
effectiveness of the intervention on reducing airway inflammation, various models were 
explored. Only baseline FeNO>25ppb (β1= -50.04), which is the cutoff level of normal range 
of FeNO,31 as well as ocular-nasal symptoms (β1=22.85) were significantly associated with  
longitudinal change in FeNO while smoking status and work-related ocular-nasal symptoms 
were of borderline significance in univariate models. Hence the use of the former two variables 
in the model. Baseline sensitisation to cereal flour allergens was added to the model due to it 
being strongly associated with FeNO in a previous study.12 The final model analysis 
demonstrated only a borderline association (p=0.088) between a ≥10% decline in FeNO and 
the intervention (OR=1.617, 95%CI: 0.930-2.810), suggesting a marginal intervention effect 
on the allergen exposure post intervention.11 
Allergic rhinitis (AR) and asthma frequently coexist in patients,32 and the presence of upper 
airway symptoms/AR is a significant predictor of occupational asthma.33 34 In the occupational 
setting, there is a strong relationship between occupational asthma and occupational rhinitis,35 
particularly in those workers exposed to HMW agents such as cereal flour dust.36 Furthermore, 
it has been demonstrated that FeNO increases progressively in AR patients without lower 
respiratory symptoms (24.5ppb, CI: 18-31 ppb), those with lower respiratory symptoms 
without asthma (38 ppb, CI: 27-49ppb), and in patients with asthma (68ppb, CI: 45-92ppb).37 
These data indicates a gradient continuum, which suggests that the total extent of airway 
inflammation depends on the degree of anatomical involvement of the airways from the nose 
to the small airways.38 This relationship between the degree of anatomical involvement and 
extent of airway inflammation could explain the FeNO decline that was stratified by the 
presence of work-related ocular-nasal symptoms at baseline. This demonstrated a significant 




(p=0.021) intervention effect on ≥10% decline in FeNO (OR=3.73, 95%CI: 1.22-11.42). 
However, this effect modification by work-related ocular-nasal symptoms could also be 
explained by the higher proportion of sensitised participants among those with work-related 
ocular-nasal symptoms compared to those who were asymptomatic (58% vs 42%, p<0.001). 
 
 This study has some important strengths, including being the only prospective trail that 
measured workplace allergen exposures levels and used FeNO as an outcome measure to 
evaluate the effectiveness of a workplace intervention. However, there were some limitations. 
Firstly, some of the bakeries in the control group applied changes to their work practices as a 
result of rotation of the managers, which diluted the strength of the effect estimates. Secondly, 
loss to follow-up was approximately 35% of the original cohort, which may have affected the 
magnitude of the effect estimate. Thirdly, the healthy worker effect may have introduced 
probable bias if there were differences among bakers that left the bakeries during this period. 
Fourthly, while the baseline questionnaire was the abbreviated version of the ECRHS 
questionnaire, the follow up final questionnaire entailed a more detailed questionnaire based 
on the non-abbreviated ECRHS questionnaire.  Although both questionnaires shared the most 
important symptom domains, this may have introduced some information bias. The use of other 
objective measures aside from FeNO such as NSBH, could have minimized this, but were not 
done due to logistic reasons. Finally, the post-intervention period was not sufficiently long 
enough to detect an appreciable improvement in health outcome parameters such as 
sensitisation. The effect of intervention on asthma and ocular-nasal symptoms is likely to be 
more demonstrable if workers were re-evaluated at 2.5-5 years after the intervention.  
In conclusion, despite these limitations, the study suggests some evidence of an intervention 
effect on airway inflammation in bakers even after one-year of follow-up. Furthermore, FeNO 
could be a useful tool to monitor the effectiveness of workplace interventions, particularly 




among those with pre-existing upper airway involvement and work-related ocular-nasal 
symptoms. Future studies should follow up participants after 2-5 years to demonstrate the 
effectiveness of workplace interventions on health outcomes. Assembling cohorts with 
exposure to different occupational allergens such as isocyanates, food processing allergens and 
animal allergens would be useful. Finally, studies should also consider using other objective 
measures to evaluate the effectiveness of interventions on allergic respiratory disease outcomes 
such as non-specific bronchial hyperresponsiveness and spirometry.
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Appendix 2: English questionnaire at baseline  
UCT OCCUPATIONAL ALLERGY AND ASTHMA STUDY AMONG 
BAKERY WORKERS IN THE WESTERN CAPE PROVINCE 
OF SOUTH AFRICA - 2006 
ENGLISH QUESTIONNAIRE 
 





      
A. IDENTIFICATION DATA 





     
  
2. First name/s 
 
____________________________________ 
     
  
3. Work number 
 
____________________________________ 
     
  
4. Date of birth: 
 
Day_____Month______Year____   








Female               (2) 
 
  
     
  
8. Interviewer's initials   ______________________ 
 
  
     
  
9. Date of interview: 






     
  
10. Bakery: _________________________________________________ 
     
  
11. Did you change your job since the last interview? 
 
  













Not applicable         (3) 
 
  
     
  






     
  




















12:00 - 21:00 (5) 
 
  
     
  
B.HEALTH PROBLEMS 
   
  
Recent chest infections  
   
  
1. Have you had the flu or sinusitis in the past 3 weeks?    
  




No                   (2) 
 
  
     
  
     
  
2. Have you had any of the following symptoms in the past 12   




    
  
2.1 chest tightness 
 
Yes                  (1)   
   
No                   (2)   
     
  
2.2 shortness of breath 
 
Yes                  (1)   
   
No                   (2)   




     
  
2.3 wheezing or whistling in your chest Yes                  (1)   
   
No                   (2)   
     
  
2.4 dry cough 
  
Yes                  (1)   
   
No                   (2)   




Yes                  (1)   
   
No                   (2)   
     
  
3. Are you being treated for Tuberculosis (TB)? 
 
  
   
Yes                  (1)   
   
No                   (2)   
     
  
3.1 If yes, for how long?  ________months         ________weeks 
     
  
If YES, to question no 3, indicate to person that the tests will not be  
done today. Schedule another appointment in three months time 
since the start of TB medication.        
     
  
Nose and eye symptoms 
   
  
4. Have you ever had any nose or eye problems due to allergies    
and/or hay fever? 
   
  
  




No                   (2) 
 
  
     
  
C. SMOKING HISTORY 
   
  
1. Do you smoke? 
   
  
  
Yes                  (1) 
 
  





No                   (2) 
 
  
     
  
1.1 If yes, have you smoked tobacco (cigarettes or pipe) for as long  
as a year? 
    
  
  




No                   (2) 
 
  
     
  
1.2 If yes, how many cigarettes per day do you smoke or    
did you smoke? 





     
  
     
  
1.3 Have you smoked (cigarettes/tobacco) in the last hour?    
  




No                   (2) 
 
  
     
  
D. ALCOHOL CONSUMPTION 
  
  
1. Do you drink alcohol? 
   
  
  




No                   (2) 
 
  
     
  




1-2 hours ago (1)   
  
1 day ago 
 
(2)   
  
1 week ago 
 
(3)   
     
  






     
  




E. MEDICATION USAGE (show booklet) 
  
  
1. Are you taking any medicine/s from a doctor or clinic at the    








No                   (2) 
 
  
     
  
1.1 If yes, what are you taking and when last did you take them? 
Names 
 




______________________ ________________ ____________ 
 
  
______________________ ________________ _____________   
     
  
F. GREEN VEGETABLE CONSUMPTION 
  
  
1. How often do you eat the following vegetable products?   
     
  
Type of  Daily 1 to 3 1 to 3  Never 
product    times a times per   
      week month   
1.1 Green  1 2 3 4 
salad           
1.2 Spinach & 1 2 3 4 
other green          
leafy vegetables           
     
  
2. When did you last consume green salad and/or spinach/other  
green leafy vegetables? 
   
  
  
1-2 hours ago (1)   
  
1 day ago 
 
(2)   
  
1 a week ago (3)   




     
  
     
  
     
  
     
  
G. PHYSICAL ACTIVITY 
   
  
1. Do you exercise? 
   
  
  




No                   (2) 
 
  
     
  




1-2 hours ago (1)   
  
1 day ago 
 
(2)   
  
1 week ago 
 
(3)   
     
  
H. SPIROMETRY/LUNG FUNCTION TEST 
 
  








No                   (2) 
 
  
     
  
2. If yes, when last did you blow into a lung function machine?   
  
1-2 hours ago (1)   
  
1 day ago 
 
(2)   
  
1 week ago 
 
(3)   
  
> a week ago (4)   
     
  
I. RECENT FOOD INTAKE 
   
  
1. Did you have anything to eat or drink in the last hour?   
  




No                   (2) 
 
  




     
  
If YES to above question, reschedule test for at least 1 hour later  
the same day or another date.        
     
  
J. WORK-RELATED SYMPTOMS 
  
  




    
  
  




No                   (2) 
 
  
     
  
2. Does being at work ever cause you to have sneezy/ 
 
  


















Appendix 3: English questionnaire at follow-up  
UCT OCCUPATIONAL ALLERGY AND ASTHMA STUDY AMONG 
BAKERY WORKERS IN THE WESTERN CAPE PROVINCE 
OF SOUTH AFRICA - 2011 
ENGLISH QUESTIONNAIRE 
 
Survey Number ________________________ 
 
      
A. IDENTIFICATION DATA 
   




      
2. First name/s ____________________________________ 










      
4. Work number ____________________________________ 
      
5. Date of birth: Day_____Month______Year____ 
      
6. Gender: 
 
Male                   (1) 
 
  
Female               (2) 
  
      
7. Home Language: English                (1) 
 
  
Afrikaans             (2) 
 





Xhosa                  (3) 
 
  
Other                   (4) 
 
      
8. Interviewer's initials   ______________________ 
 
      
9. Date of interview: 




      
10. Bakery: _________________________________________________ 
      
11. Are you a casual or permanent worker? 
 
  
Casual (VTE)       (1) 
 
  
Permanent          (2) 
 
      
      
      
      
      
12. Were you part of the previous surveys? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
12.1 If yes, which year: 
   
 
2003 Yes                  (1) 
  
  
No                   (2) 
  
      
 
2007 Yes                  (1) 
  
  
No                   (2) 
  




      
B.HEALTH PROBLEMS 
   
      
Wheeze and tightness in the chest 
  
      
1. Have you ever had  wheezing or whistling in your  
chest in the past? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 1.1 
  
 
If NO, skip to Question 
2 
   
      
1.1 If yes, when was the first time you had these  
 
symptoms. 
     
      
Date: Month ______  Year _____ 
  
      
1.2 Have you had wheezing or whistling in your chest at  
any time in the last 12 months?  
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 1.2.1 
  
 
If NO, skip to Question 
2 
   
      




1.2.1 Have you been short of breath when the wheezing 
 noise was present? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
1.2.2 Have you had this wheezing or whistling when you  
did not have a cold or flu? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
2. Have you been woken up with a feeling of tightness  
in your chest at any time in the last 12 months? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
Shortness of breath 
    
      
3. Have you had an attack of shortness of breath that  
came on during the daytime when you were at rest at  
any time in the last 12 months? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
4. Have you had an attack of shortness of breath that  
came on following running or exercise at any time in the 




 last 12 months? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
5. Have you been woken by an attack of shortness of  
breath at any time in the last 12 months? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
Cough and phlegm from the chest 
  
      
6. Have you been woken by an attack of coughing at any 
 time in the last 12 months? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
7. Do you usually cough first thing in the morning? 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
8. Do you usually cough during the rest of the day, or  
at night? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 8.1 
  





If NO, skip to Question 
9 
   
      
      
8.1 Do you cough like this on most days/nights for as 
 much as three or more months in each of the last  
 
two years? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
9. Do you usually bring up any phlegm from your chest  
first thing in the morning? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
10. Do you usually bring up any phlegm from your chest  
during the day, or at night? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 10.1 
  
 
If NO, skip to Question 11 
  
      
10.1 Do you bring up phlegm like this on most days/ 
nights for as much as three or more months in each of  
the last two years? 
    





Yes                  (1) 
  
  
No                   (2) 
  
      
Breathing 
     
      
11. Do you ever have trouble with your breathing? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 11.1 
  
 
If NO, skip to Question 12 
  
      
11.1 Do you have this trouble: 
   
      
 
Give all options at once 
   
 
Insert a cross (X) next to one answer only 
 
      
a) continuously so that your breathing is never  
 
quite right? 
    
______ 
b) repeatedly, but it goes away completely  
  
between the times when it troubles you? 
 
______ 
c) only rarely? 
   
______ 
      
      
12. Are you disabled from walking by a condition other  
than heart or lung disease? 
   
  
Yes                  (1) 
  





No                   (2) 
  
      
If YES, state the condition _______________________________________ 
 and go on to Question 13 
    
If NO, go to Question 12.1 
    
      
12.1 Are you troubled by shortness of breath when   
 hurrying on level ground or walking up a slight hill? 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 12.1.1 
  
 
If NO, skip to Question 13 
  
      
12.1.1 Do you get short of breath walking with other  
people of your own age on level ground? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
12.1.1.1 Do you have to stop for breath when walking at  
your own pace on level ground? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
Asthma 
     
      
13. Have you ever had asthma?  
   





Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 13.1 
  
 
If NO, skip to Question 13.8 
  
      
13.1 If yes, was this confirmed by a doctor? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.2 How old were you when you were told you have  
asthma? 
     
      
Give all options at once  
    
Insert a cross (X) next to one answer only 
   
      
a)  Only before you were 17 years old              ____ 
 
b)  Only at the age of 17 years or older            ____ 
 
c)  Both                                                            ____ 
      
The following references to "attack" of asthma refers to episodes of   
 
wheezing, shortness of breath, chest tightness or cough attributed  
to asthma 
     
      
13.3.1 How old were you when you had your first attack  
of asthma? 
     
 
________ years old 
   
      




13.3.2 How old were you when you had your most  
 
recent attack of asthma? 
   
 
________ years old 
   
      
13.4.1-6 Which months of the year do you usually have  
attacks of asthma? 
    
      
13.4.1 January/February 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.4.2 March/April 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.4.3 May/June 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.4.4 July/August 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.4.5 September/October 
   
  
Yes                  (1) 
  
  
No                   (2) 
  




      
13.4.6 November/December 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.5 Have you had an attack of asthma in the last  
 
12 months? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 13.5.1 
  
 
If NO, skip to Question 13.6 
  
      
13.5.1 How often have you had an attack of asthma in  
the last 12 months? 
    
      
 
Give all options at once  
   
 
Insert a cross (X) next to one answer only 
 
      
 








c) More than 1 time per month ______ 
 
d) 3 to 12 times in the whole year ______ 
 
e) 1 to 2 times in the whole year ______ 
      
13.6 Are your chest symptoms caused by, or made  
 worse by any of the following: 
   




      
 
Answer all questions 
   
      
13.6.1 Contact with animals/pets 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.6.2 Grass or flowers 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.6.3 Heavy exercise 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.6.4 Breathing cold air 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.6.5 Dusts or sprays at work 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.6.6 Tobacco smoke 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      




13.6.7 Change in the weather 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.7 Do your chest symptoms seem better or worse  
when you are away from work (for example, on  
 
weekends, off-shift and vacations)? 
  
      
 
Give all options at once  
   
 
Insert a cross (X) next to one answer only 
 
      
 
a)  Stay the same ______ 
  
 
b)  Get better ______ 
  
 
c)  Get worse ______ 
  
      
13.8 Does being at work ever make your chest tight  
or wheezy? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 13.8.1  
  
 
If NO, skip to Question 13.9 
  
      
13.8.1 When  did you first notice having problems with  
chest tightness or wheeze at work? 
  
      
Date: Month ______  Year _____ 
  




      
13.8.2 Is there anything that you work with that causes  
you to have these chest  symptoms? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
If YES, go on to Question 13.8.3 (specify wheat, rye &/or premix)  
or any other substance 
    
 
If NO, skip to Question 13.9 
  
      
13.8.3 What do you think is causing these symptoms?  
 
________________________________________________________ 
      
13.9 Have you ever had to change or leave your work  
area, either temporarily or permanently, in this bakery 
 or any other bakery because of any chest symptoms?  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 13.9.1  
  
 
If NO, skip to Question 13.10 
  
      
13.9.1 What type of job were you doing when this  
 
happened?  
     
__________________________________________________ 
 
      
13.9.2 Was this a job in this bakery?  
  





Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 13.9.2.1  
  
 
If NO, skip to Question 13.10 
  
      




      




      
13.9.2.3 Did your symptoms improve when you changed 
 jobs?  
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.10 Have you ever worked in a job or jobs that  
 
exposed you to vapours, gas, dust or fumes?  
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 13.10.1. 
  
 
 List the jobs beginning with the most recent 
 
 
If NO, skip to Question 13.11 
  
      
      
      




13.10.1 What was or is this job? ______________________ 
 
(if current job write 'current job') 
 
      
13.10.2 Before that? ___________________________________ 
      
13.10.3 Before that? __________________________________ 
      
13.11 Has there ever been an instance when you inhaled 
 a large amount of vapour, gas, dust or fumes in any of  
these jobs that resulted in you developing a tight chest,  
wheeze or cough?  
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 13.11.1.  
  
 
If NO, skip to Question 13.12 
  
      
13.11.1 What was or is this job? ________________________ 
 
(if current job write 'current job') 
 
      
13.12 Are you using any medicines, including inhalers/ 
pumps, nebulizers, syrups or tablets, for asthma or  
breathing problems? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
If YES, go on to Question 13.12.1, showing examples of each 
 





If NO, skip to question 13.13 
  
      
13.12.1 Which medicines?  










      
13.12.2 Do you take these medicines every day even  
when you do not have any trouble breathing? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
13.13 Have you ever been treated for any of the  
 
following: 
     
 
Answer all questions 
   
      
13.13.1 Repeated chest infections as a child 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
  
UNK                (3) 
  
      
13.13.2 Tuberculosis (TB) 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
  
UNK                (3) 
  
      




13.13.3 Chronic bronchitis 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
  
UNK                (3) 
  
      
Nose and eye symptoms 
   
      
14. Have you ever had any nose or eye problems or  
allergies such as hay fever? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
If YES, go on to Question 14.1 Answer all questions 
  
 
If NO, skip to Question 14.4 
  
      
14.1 How old were you when you first noticed these  
symptoms?  
     
  
__________ years old 
 
      
14.2 During the past 12 months have you had two or  
more episodes of: 
    
14.2.1 sneezy, itchy or runny nose when you did not 
 have a cold or flu? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      




14.2.2 red, itchy or watery eyes 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
      
14.2.3 Do you usually have the nose or eye symptoms  
at any particular time of the year? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
14.2.3.1 If YES, which is the worst season? 
  
      
 
Give all options at once  
   
 
Insert a cross (X) next to one answer only 
 
      
 









c)  Summer __________ 
 
 
d)  Autumn  __________ 
 
      
If YES to any of the above in question 14.2, go on to Question 14.3 
 
If NO, skip to Question 14.4 
  
      
14.3 Do your nose or eye symptoms seem better or 
 
 worse  when you are away from work (for example, on  
weekends, off-shift and vacations)? 
  
      





Give all options at once  
   
 
Insert a cross (X) next to one answer only 
 
      
 
a)  Stay the same _________ 
  
 
b)  Get better _________ 
  
 
c)  Get worse  _________ 
  
      
14.4 Does being at work ever cause you to have sneezy/ 
itchy/runny nose or red/itchy/watery eyes? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
If YES to any one of the above, go on to Question 14.4.1 
 
If NO, skip to Question 14.5 
    
      
14.4.1 Since when have you been having these  
 
symptoms at work? 
    
      
Date:           Month ____ Year ____ 
   
      
14.4.2 Is there anything that you work with that causes 
 you to have these symptoms? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
      
      
If YES, go on to Question 14.4.3 (specify wheat, rye &/or premix)  
or any other substance 
    





If NO, skip to Question 14.5 
  
      
14.4.3 What do you think is causing these symptoms?  
________________________________________________________________ 
      
14.5 Are you using any medicines, including nose  
 
sprays, drops, tablets or injections, for any nose or eye  
symptoms at present? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 14.5.1 
  
 
If NO, go on to Question 14.6 
  
      
Present a chart with different samples of allergy medicines  
 
(N.B. a worker might show you his/her medicines).  
  
      
14.5.1 Which medicines?  





      
14.6 Did you have hay fever (itchy or watery eyes/nose)  
as a child? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
Other allergic conditions 
   
15. Did you have eczema as a child? 
  





Yes                  (1) 
  
  
No                   (2) 
  
      
16. Are you allergic to insect stings or bites? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 16.1 
  
 
If NO, skip to Question 17 
  
      
16.1.1-3 What kind of reactions do you have? 
 
      
16.1.1 Breathing difficulty, feeling faint, fever? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
16.1.2 Redness, itching or swelling at the sting site 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
16.1.3 Other: _______________________________ 
 
      
17. Have you ever had any difficulty with your breathing  
after taking medications or injections that you did not  
have before? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      





If YES, go on to Question 17.1 
  
 
If NO, skip to 18.1 
   
      
17.1 Which medicines?  
   
_________________ __________________________________________ 
      
18.1-6 When you are near animals (such as cats, dogs  
or horses), near feathers (including pillows, quilts or  
duvets), near grass and flowers, or in a dusty part of the  
house, do you ever 
    
      
18.1 Start to cough? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
18.2 Start to wheeze? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
18.3 Get a tight chest?  
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
18.4 Start to feel short of breath? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      




18.5 Get a runny/stuffy nose or sneeze? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
18.6 Get itchy or watery eyes? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
18.7 Get itchy skin/rash? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
19. Have you ever had an illness or trouble caused by 
 eating a particular type of food/fruit? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 19.1 
  
 
If NO, skip to 20 
   
      
19.1 What type of food/fruit was this?  
  
_________________________________________________________ 
      
19.1.1-6 Did this illness or trouble include: 
 
      
19.1.1 Itchy skin or rash  
   
  
Yes                  (1) 
  





No                   (2) 
  
      
19.1.2 Diarhoea or vomiting 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
19.1.3 Runny or stuffy nose 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
19.1.4 Severe headaches  
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
19.1.5 Breathlessness/tight chest/wheeze 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
19.1.6 Other:________________________________________  
      
19.2 Was the food canned or preserved? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
  
UNK                (3) 
  
      
19.3 Do you experience these problems when you drink 




 fizzy drinks also? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
C. FAMILY HISTORY 
    
      
1. Do/did any members of your family (blood relatives)  
ever have any kind of allergies? 
   
      
Do not include relatives by marriage 
   
 If family history is completely unknown (subject is adopted, etc.), 
 mark  UNK and do not complete table. Move to next section 
 
      
  
Yes                  (1) 
  
  
No                   (2) 
  
  
UNK                (3) 
  
      
If YES, complete table below. Insert a cross (X) in the appropriate  
 
block for each option 
    
      
Type of  NO ONE YES, present in the family Do Not 
Allergy in family Parent Brother/ Child Know 
   
Sister 
  
      
1.1 Hay fever 1 2 3 4 5 
      
1.2 Eczema  1 2 3 4 5 
      
1.3 Asthma 1 2 3 4 5 
      




1.4 Wheat 1 2 3 4 5 
related allergy 
     
      
1.5 Other  1 2 3 4 5 
 allergy 
     
Specify: 
     
______________ 
     
______________ 
     
      
      
D. SMOKING HISTORY 
   
      
1. Have you ever smoked tobacco (cigarettes or pipe) for  
as long as a year? 
    
      
‘YES’ means at least 20 packs of cigarettes or 360 grams of tobacco 
 in a lifetime  or at least one cigarette per day for one year 
 
      
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 1.1 
  
 
If NO, skip to Question 
2 
   
      
1.1 How old were you when you started smoking? 
 
      
 
__________ years old 
   
      
1.2 Do you now smoke? 
   
      




‘YES’ means smoking tobacco in the last month or more 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 1.2.1 
  
 
If NO, skip to Question 1.3.1 
  
      
1.2.1-2. How much do you now smoke on average? 
 
      
1.2.1 Number of cigarettes per day ________ 
 
      




      
1.3. Have you stopped smoking completely? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 1.3.1 
  
 
If NO, skip to Question 1.4 
  
      
1.3.1. How old were you when you stopped smoking  
completely? 
     
 
__________ years old 
   
      
1.3.1.1 How many years in total did you smoke  
 
cigarettes? (Do not include the years you stopped before  
you started again)   
    
 
__________ years 
   
      




1.3.2.1-2 On average of the entire time you smoked,  
how much did you smoke? 
   
      
1.3.2.1 Number of cigarettes per day  _______ 
 
      
1.3.2.2 Pipe tobacco in grams/week   _______ 
 
      
1.4 Do you or did you inhale the smoke? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
      
      
      
2. Have you been regularly exposed to tobacco smoke 
 from other people smoking cigarettes or pipe in the last  
12 months? 
     
      
‘Regularly’ means on most days or nights 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
E. DIETARY HISTORY/DOMESTIC ACTIVITIES 
 
      
1. How often have you eaten the following grain  
 
products in the last 12 months? 
   
      
Go through each wheat product option and insert a cross (X) in the  
block for each option 
    
      




Type of wheat  Daily 1 to 3 1 to 3  Never 
product 
 
 times a times per 
 
  
  week month 
 
     
1.1 White 1 2 3 4 
bread/Rolls  
    
1.2 Brown  1 2 3 4 
bread/Rolls  
    
1.3 Whole  
    
wheat bread/ 1 2 3 4 
rolls 
     
1.4 Rye bread/ 1 2 3 4 
rolls 
    
2. Pastries 1 2 3 4 
     
3. Cereals 1 2 3 4 
     
4. Biscuits 1 2 3 4 
containing 
    
wheat 
    
     
5.Pasta 1 2 3 4 
containing 
    
wheat 
    
     
6. Other 1 2 3 4 
Specify: 
    
_____________ 
    
_____________ 
    




     
      
2.Have you changed your diet or avoided certain grain 
(eg. wheat/rye/soya) products  because they do not   
agree with you when you eat them? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 2.1 
  
 
If NO, skip to Question 
3 
   
      






      
3. Do you bake at home? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If YES, go on to Question 3.1 
  
 
If NO, go to Question 4 
   
      
3.1 How often do you do baking at home? 
  
 











c) 2-3 times per week ________ 
 














      
3.2 What do you bake? 






















      
  Specify:___________________________________ 
 
      
4. Does any one else bake at home? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
F. WORK HISTORY IN THE BAKERY INDUSTRY 
 
      
1. How long have you been working at this bakery?         
  
__________ years  
  
  
__________ months  
  
      
Present job 
     
      
2. How long have you been working in your current        
job?   
     





__________ years  
  
  
__________ months  
  
      
3. In which area/section are you currently working?  
_________________________________________________________ 
      
3.1 What is your job in this area/section?  
  
      
Job Title: _____________________________________ 
 
      






Yes                  (1) 
   
No                   (2) 





Yes                  (1) 
   
No                   (2) 
      
 
c) croissants Yes                  (1) 
   
No                   (2) 
      
 
d) bread,rolls Yes                  (1) 
   
No                   (2) 
      
 
e) cakes/tarts Yes                  (1) 
   
No                   (2) 
      








Yes                  (1) 
   
No                   (2) 
      
 
g) confectionary  Yes                  (1) 
   
No                   (2) 




Yes                  (1) 
   
No                   (2) 
Specify:___________________________________ 
 
      
      
3.3 What ingredients do you work with? 
  
 
a) Flour (wheat, rye) 
   
   
Yes                  (1) 
   
No                   (2) 
      
 
b) Baking additives (premix) 
  
   
Yes                  (1) 
   
No                   (2) 
      
 
c) Icing sugar 
   
   
Yes                  (1) 
   
No                   (2) 
      
 
d) Nuts (peanuts, hazelnuts) 
  




   
Yes                  (1) 
   
No                   (2) 
      
 
e) Seeds (sesame, lupine) 
  
   
Yes                  (1) 
   
No                   (2) 




Yes                  (1) 
   
No                   (2) 
Specify:___________________________________ 
 
      
3.4 Do you ever do other jobs during your shift on a  
regular basis (almost every day)? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
If Yes, which jobs?   __________________________________ 
  
__________________________________ 
      
3.5 How much dust would you say your current job 
 produces: 
     
      
 
Give all options at once  
   
 
Insert a cross (X) next to one answer only 
 

















c) An average amount _______ 
 
 




      
      
      
      
      
3.5.1 What aspect of your work would you say is 
 
 very dusty? 
     
 
a) Tipping/Dispensing  
  
   
Yes                  (1) 
   
No                   (2) 
   
N/A                 (3) 
      
 
b) Weighing 
   
   
Yes                  (1) 
   
No                   (2) 
   
N/A                 (3) 




    
   
Yes                  (1) 
   
No                   (2) 
   
N/A                 (3) 
      







    
   
Yes                  (1) 
   
No                   (2) 
   
N/A                 (3) 
      
 
e) brushing table 
   
   
Yes                  (1) 
   
No                   (2) 
   
N/A                 (3) 
      
 
f) dough handling 
   
   
Yes                  (1) 
   
No                   (2) 
   
N/A                 (3) 
      
 
g) other 
    
   
Yes                  (1) 
   
No                   (2) 
   
N/A                 (3) 
      
Specify:___________________________________ 
 
      
3.5.1.1 What type of cleaning activities in your daily 
work are very dusty. 
    




3.5.1.1.1 Cleaning work table surfaces? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
      
3.5.1.1.2 Sweeping floors? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.5.1.1.3 Cleaning equipment (mixers, cutters) 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.5.2 How far do you work from the source of the dust? 
      
 
Give all options at once  
   
 
Insert a cross (X) next to one answer only 
 
      
 
a) Right next to the source _______ 
 
 
b) About 1-2 metres away _______ 
 
 
c) More than 3 metres away _______ 
 
 




      
3.6 Do you use any respiratory protective equipment/ 




mask on a regular basis (almost every day) while doing  
your job? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If NO, skip to Question 
4 
   
 
If YES, continue with Question 3.6.1 
 
      
3.6.1 Which type of mask (show respirators)?  
 
      
3.6.1.1 FFP2 
 
Yes                  (1) 
  
  
No                   (2) 
  
      
3.6.1.2 Paper Yes                  (1) 
  
  
No                   (2) 
  
      
3.6.1.3 Other:_________________________________ 
 
      
3.6.2 For which tasks do you use the mask? 
 
      
3.6.2.1 Pouring flour into mixer 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
      
      
3.6.2.2 Cleaning Yes                  (1) 
  





No                   (2) 
  
      
3.6.2.3 Maintenance of machinery 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
3.6.2.4 Other: __________________________________ 
      
3.7 Which of the following methods of dust control in  
the bakery have you found useful in your daily work 
activities?  
     
      
3.7.1 Rubbing table with flour? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.7.2 Using a sieve to dust table? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.7.3 Using oil instead of flour on dough table? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  




      
3.7.4 Cleaning floors with a bristle broom? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.7.5 Cleaning floors with a bristle broom and water? 
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.7.6 Cleaning floors using a rubber scraper? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.7.7 Cleaning floors using a microfibre mop? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.7.8 Cleaning floors with a "spaghetti" mop? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      




3.7.9 Cleaning with a vacuum cleaner? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.7.10 Using a mixer with a lid and flap? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
3.7.11 Starting the mixer on a slow speed? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
Previous jobs in current bakery 
   
      
4.Have you changed your job since your last interview 
(2003/2007)? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If NO, skip to question 
5 
   
 
If YES, continue with question 4.1 
  
      
4.1 What other jobs did you do here since then? 
 




      
Start with the first job that you changed to and work forward. 
      
No Job From To Years  Months 
1 
     
2 
     
3 
     
4 
     
5 
     
      
Previous work in other bakeries 
   
      
5. Have you worked in any other bakeries beside 
 
Pick 'n Pay? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
 
If NO, skip to Section G 
   
 
If YES, continue with question 5.1 
  
      
5.1 What is the total amount of time you have worked in  
the bakery industry before you started working in  
 
this bakery? 
     
  
Years______ Months ______   
      
5.2 Why did you change jobs? 





      




G. HEALTH AND SAFETY EDUCATION AND TRAINING 
      
1. Have you had any health and safety education and  
training on how to protect yourself when working with  
flour dust? 
     
  
Yes                  (1) 
  
  
No                   (2) 
  
      
2.1 If yes, what form of training? 
   
      
2.1.1 On the job training? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
2.1.2 Dust control video presentation 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
2.1.3 Dust control handbook?  
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
2.1.4 Posters in your bakery 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
      




      
      
2.1.5 Manager's workshops conducted by UCT 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
  
N/A                 (3) 
  
      
2.1.6 Other?  Yes                  (1) 
  
  
No                   (2) 
  
      
Specify:________________________________________ 
 
      








Appendix 4: Exhaled nitric oxide /PFT pre-test data collection sheet  
UCT OCCUPATIONAL ALLERGY AND ASTHMA STUDY AMONG 
BAKERY WORKERS IN THE WESTERN CAPE PROVINCE 
OF SOUTH AFRICA - 2011 






      
A. IDENTIFICATION DATA 




      
2. First name/s 
 
____________________________________ 
      
3. Work number 
 
____________________________________ 
      




      
5. Interviewer's initials   ______________________ 
  
      
6. Date of interview: 




      
7. Bakery: _________________________________________________ 
      
      
B.HEALTH PROBLEMS 
    
Recent chest infections  
    
1. Have you had the flu or sinusitis in the past 3 weeks?  
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      




2. Are you being treated for Tuberculosis (TB)? 
  
   
Yes                  (1) 
 
   
No                   (2) 
 
      
2.1 If yes, for how long?  ________months         ________weeks 
      
If YES, to question no 2, indicate to person that the tests will not be  
done today. Schedule another appointment in three months time 
since the start of TB medication.  
   
      
      
      
      
      
      
      
3. Have you had a heart attack or stroke in the last 3 months?    
   
Yes                  (1) 
 
   
No                   (2) 
 
      
4. Do you have epilepsy?  
    
   
Yes                  (1) 
 
   
No                   (2) 
 
      
5. Have you had any recent operation (in the last 12 months)?     
If Yes, what type and how many months ago?  
  





      
If YES to any of the above Q3-5, indicate to the person that the  
 
lung function tests will not be done.  If NO, proceed with the rest  
of the screening questions 
    
      





     
      
6.1 Are you Pregnant?     
 
Yes                  (1) 
 
   
No                   (2) 
 
      
6.2 Are you Breastfeeding?  
 
Yes                  (1) 
 
   
No                   (2) 
 
      
If Pregnant, indicate to the person that the Lung Function Test will  
not be done today, but proceed with NIOX  
  
      
If Breastfeeding, proceed with Lung Function Test with Post- 
 
Bronchodilator.  Proceed with the rest of the screening questions. 
      
C. ALCOHOL CONSUMPTION 
   
1. Do you drink alcohol? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
1.1 If yes, when have you last consumed alcohol?  
  
  
1-2 hours ago (1) 
 
  









      
1.2 How much alcohol did you consume? 
   
_________________________________________________ 
        
      
D. MEDICATION USAGE (show booklet) 
   
1. Are you taking any medicine/s from a doctor or clinic at the  
 
moment for asthma, and or hayfever? 
   





Yes                  (1) 
  
  
No                   (2) 
  
      
1.1 If yes, what are you taking and when last did you take them? 
Names 
 
                   No. of hours since last dose 
_______________________________ ____________ 
  
______________________ ________________ ____________ 
  
______________________ ________________ _____________ 
 
      
2. Are you taking any medicine/s from a doctor or clinic at the 
 
 moment for any heart condition, or your eyes?  
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
If short-acting beta-2-agonist or anti-cholinergic inhalers used in  
the last 4 hours or long-acting MDI or theophylline used in last 8  
hours, reschedule spirometry and counsel accordingly. 
  
      
E. GREEN VEGETABLE CONSUMPTION 
   
1. How often do you eat the following vegetable products? 
 
      
Type of  Daily 1 to 3 1 to 3  Never 
product 
 
 times a times per 
 
  
  week month 
 
1.1 Green  1 2 3 4 
salad 
     
1.2 Spinach & 1 2 3 4 
other green  
    
leafy vegetables 
     
      




2. When did you last consume green salad and/or spinach/other  
green leafy vegetables? 
    
  
1-2 hours ago (1) 
 
  










      
F. PHYSICAL ACTIVITY 
    
1. Do you exercise? 
    
  
Yes                  (1) 
  
  
No                   (2) 
  
      
2. When was the last time you exercised?  
   
  
1-2 hours ago (1) 
 
  









      
      
G. SPIROMETRY/LUNG FUNCTION TEST 
  
1. Have you ever had a spirometry/lung function test? 
  
  
Yes                  (1) 
  
  
No                   (2) 
  
      
2. If yes, when last did you blow into a lung function machine? 
 
  
1-2 hours ago (1) 
 
  















      




H. RECENT FOOD INTAKE 
    
1. Did you have anything to eat or drink in the last hour? 
 
  
Yes                  (1) 
  
  
No                   (2) 
  
      
2. Have you smoked in the last hour? 
   
  
Yes                  (1) 
  
  
No                   (2) 
  
      
If YES to above questions, reschedule NIOX test for at least 1 hour 
 later the same day or another date.  
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Ambient NO concentration (ppb)  _________________ 
 
      
Ambient temperature (degrees celcius) __________________ 
 
      




   
diastolic ___________ 
      




      
3.1 Subject's height (in centimetres) ___________________ 
 
      
3.2 Subject's weight (in kilograms) ___________________ 
 
      
4. Gender: 
 
Male                   (1) 
  
  
Female               (2) 
  
      
5. Effort number (start) ____________ 
   
      
6.1 FENo measurement (ppb) 1st effort  
 
____________ 
NIOX machine number of efforts completed  ____________ 
      
6.2 FENo measurement (ppb) 2nd effort 
 
____________ 
NIOX machine number of efforts completed  ____________ 
      




7. FENO printout 
appended 
    
  
Yes                  (1) 
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Appendix 7: Occupational and Environmental Medicine journal guidelines 
 
GENERAL INSTRUCTIONS1  
Occupational and Environmental Medicine is an international peer reviewed journal covering 
current developments in occupational and environmental health worldwide. Occupational and 
Environmental Medicine publishes high-quality research relating to the full range of chemical, 
physical, ergonomic, biological and psychosocial hazards in the workplace and to 
environmental contaminants and their health effects. The journal welcomes research aimed at 
improving the evidence-based policy and practice of occupational and environmental research; 
including the development and application of novel biological and statistical techniques in 
addition to evaluation of interventions in controlling occupational and environmental risks. 
Editorial policy 
Occupational and Environmental Medicine adheres to the highest standards concerning its 
editorial policies on publication ethics, scientific misconduct, consent and peer review criteria. 
To view all BMJ Journal policies please refer to the BMJ Author Hub policies page. 
Articles are published under an exclusive licence (or non-exclusive licence for UK Crown and 
US Federal Government employees) and authors retain copyright. Articles can also be 
published under a Creative Commons licence to facilitate reuse of the content; please refer to 
the Occupational and Environmental Medicine Copyright Author Licence Statement. 
 
Presentation of statistical data 
We strongly encourage authors to observe the following guidelines: 
• Only essential tables and graphs should be included. Large tables should be kept to a 
minimum. 
• Epidemiological measures of association (e.g. ratios or differences of rates, risks, odds, 
or prevalences) are preferred for contrasts of disease occurrence. 




• Confidence intervals should be reported for measures of association. 
• P-values may be reported if necessary for tests such as trend tests or non-parametric 
tests etc but should be given as quantitative values e.g. p=0.032 rather than relative to 
a cut point e.g. p<0.05. 
• Generally numerical findings should not be reported to more than 1 or 2 decimal places. 
• The approach to carrying out any statistical modelling should be described, including 
strategies for selection of explanatory variables and goodness of fit. The models 
presented in the paper should be clearly described and justified, with appropriate 
references given. 
• Results from observational studies (cohort, case-control, or cross-sectional designs) 
should be reported following the guidelines in the STROBE statement, results of 
randomised trials should be reported following the CONSORT guidelines, and 
systematic reviews and meta-analyses should follow the PRISMA guidelines. 
Article publishing charges 
During submission, authors can choose to have their article published open access for 1950 
GBP (exclusive of VAT for UK and EU authors). Authors can also choose to publish their 
article in colour for the print edition – instead of the default option of black and white – for 250 
GBP. There are no submission, page or online-only colour figure charges. 
For more information on open access, funder compliance and institutional programmes please 
refer to the BMJ Author Hub open access page. 
Submission guidelines 
Please review the below article type specifications including the required article lengths, 
illustrations, table limits and reference counts. The word count excludes the title page, abstract, 
tables, acknowledgements, contributions and references. Manuscripts should be as succinct as 
possible. 
For further support when making your submission please refer to the resources available on 




Authors should also provide key messages with original research submissions under the 
following headings: 
1. What is already known about this subject? 
2. What are the new findings? 
3. How might this impact on policy or clinical practice in the foreseeable future? 
Word count: up to 3,500 
Structured abstract: up to 250 words; ‘Objectives’, ‘Methods’, ‘Results’, ‘Conclusions’ 




Tables/Illustrations: up to 5 
References: up to 40 
 
 
MANUSCRIPT FORMAT2  
General instructions 
The manuscript must be submitted as a Word document (BMJ Case Reports and Veterinary 
Record Case Reports request that authors submit using a template which should also be in 
Word format). PDF is not accepted. 
 
The manuscript should be presented in the following order: 
• Title page. 
• Abstract, or a summary for case reports (Note: references should not be included in 
abstracts or summaries). 
• Main text separated under appropriate headings and subheadings using the following 
hierarchy: BOLD CAPS, bold lower case, Plain text, Italics. 
• Tables should be in Word format and placed in the main text where the table is first 
cited. Tables should also be cited in numerical order. 
• Acknowledgments, Competing Interests, Funding and all other required statements. 
• References. All references should be cited in the main text in numerical order. 
Figures must be uploaded as separate files (view further details under the 
Figures/illustrations section). All figures must be cited within the main text in numerical 
order and legends should be provided at the end of the manuscript. 
Online Supplementary materials should be uploaded using the File Designation 
“Supplementary File” on the submission site and cited in the main text. 
 
Style 
Acronyms and abbreviations should be used sparingly and fully explained when first 
used. Abbreviations and symbols must be standard. SI units should be used throughout, except 
for blood pressure values which should be reported in mm Hg. 
Whenever possible, drugs should be given their approved generic name. Where a proprietary 
(brand) name is used, it should begin with a capital letter. 
 
Figures/illustrations 




Images must be uploaded as separate files. All images must be cited within the main text in 
numerical order and legends must be provided (ideally at the end of the manuscript). 
Video: How to improve your graphs and tables  
 
Colour images and charges 
For certain journals, authors of unsolicited manuscripts that wish to publish colour figures in 
print will be charged a fee to cover the cost of printing. Refer to the specific journal’s 
instructions for authors for more information. 
Alternatively, authors are encouraged to supply colour illustrations for online publication and 
black and white versions for print publication. Colour publication online is offered at no charge, 
but the figure legend must not refer to the use of colours. 
Detailed guidance on figure preparation  
 
File types 
Figures should be submitted in TIFF or EPS format. JPEG files are acceptable in some cases. 
A minimum resolution of 300 dpi is required, except for line art which should be 1200 dpi. 
Histograms should be presented in a simple, two-dimensional format, with no background grid. 
For figures consisting of multiple images/parts, please ensure these are submitted as a single 
composite file for processing. We are unable to accept figures that are submitted as multiple 
files. 
During submission, ensure that the figure files are labelled with the correct File Designation of 
“Mono Image” for black and white figures and “Colour Image” for colour figures. 
Figures are checked using automated quality control and if they are below the minimum 
standard you will be alerted and asked to resupply them. 
Please ensure that any specific patient/hospital details are removed or blacked out (e.g. X-rays, 
MRI scans, etc). Figures that use a black bar to obscure a patient’s identity are NOT accepted 
 
Tables 
Tables should be in Word format and placed in the main text where the table is first cited. 
Tables must be cited in the main text in numerical order. Please note that tables embedded as 
Excel files within the manuscript are NOT accepted. Tables in Excel should be copied and 
pasted into the manuscript Word file. 
Tables should be self-explanatory and the data they contain must not be duplicated in the text 
or figures. Any tables submitted that are longer/larger than 2 pages will be published as online 
only supplementary material. 
 
References 




Authors are responsible for the accuracy of cited references and these should be checked before 
the manuscript is submitted. 
Citing in the text 
References must be numbered sequentially as they appear in the text. References cited in 
figures or tables (or in their legends and footnotes) should appear at the end of the reference 
list to avoid re-numbering if tables and figures are moved around at peer review/proof stage. 
Reference numbers in the text should be inserted immediately after punctuation (with no word 
spacing)—for example,[6] not [6]. 
Where more than one reference is cited, these should be separated by a comma, for example,[1, 
4, 39]. For sequences of consecutive numbers, give the first and last number of the sequence 
separated by a hyphen, for example,[22-25]. References provided in this format are translated 
during the production process to superscript type, and act as hyperlinks from the text to the 
quoted references in electronic forms of the article. 
Please note that if references are not cited in order the manuscript may be returned for 
amendment before it is passed on to the Editor for review. 
 
Preparing the reference list 
References must be numbered consecutively in the order in which they are mentioned in the 
text. 
Only papers published or in press should be included in the reference list. Personal 
communications or unpublished data must be cited in parentheses in the text with the name(s) 
of the source(s) and the year. Authors should request permission from the source to cite 
unpublished data. 
 
Journals from BMJ use a slightly modified version of Vancouver referencing style (see 
example below, or download here). Note that The BMJ uses a different style (please see 
below). 
 
BMJ reference style 
List the names and initials of all authors if there are 3 or fewer; otherwise list the first 3 and 
add ‘et al.’ (The exception is the Journal of Medical Genetics, which lists all authors). Use one 
space only between words up to the year and then no spaces. The journal title should be in italic 
and abbreviated according to the style of Medline. If the journal is not listed in Medline then it 
should be written out in full. 
Check journal abbreviations using PubMed  








13 Koziol-Mclain J, Brand D, Morgan D, et al. Measuring injury risk factors: question 
reliability in a statewide sample. Inj Prev 2000;6:148–50. 
Chapter in book 
14 Nagin D. General deterrence: a review of the empirical evidence. In: Blumstein A, 
Cohen J, Nagin D, eds. Deterrence and Incapacitation: Estimating the Effects of 
Criminal Sanctions on Crime Rates. Washington, DC: National Academy of Sciences 
1978:95–139. 
Book 
15 Howland J. Preventing Automobile Injury: New Findings From Evaluative 
Research. Dover, MA: Auburn House Publishing Company 1988:163–96. 
Abstract/supplement 
16 Roxburgh J, Cooke RA, Deverall P, et al. Haemodynamic function of the 
carbomedics bileaflet prosthesis [abstract]. Br Heart J 1995;73(Suppl 2):P37. 
Electronic citations 
Websites are referenced with their URL and access date, and as much other 
information as is available. Access date is important as websites can be updated and 
URLs change. The “date accessed” can be later than the acceptance date of the 
paper, and it can be just the month accessed. 
Electronic journal articles 
Morse SS. Factors in the emergency of infectious diseases. Emerg Infect Dis 1995 
Jan-Mar;1(1). www.cdc.gov/nciod/EID/vol1no1/morse.htm (accessed 5 Jun 1998). 
Electronic letters 
Bloggs J. Title of letter. Journal name Online [eLetter] Date of publication. url eg: 
Krishnamoorthy KM, Dash PK. Novel approach to transseptal puncture. Heart Online 
[eLetter] 18 September 2001. http://heart.bmj.com/cgi/eletters/86/5/e11#EL1 
Legal material 
Toxic substances Contro Act: Hearing on S776 Before the Subcommittee of the 
Environment of the Senate Comm. on Commerce, 94th Congress 1st September 
(1975). 
Washington v Glucksberg 521 US 702 (1997) 
Law references 
The two main series of law reports, Weekly Law Reports (WLR) and All England Law 
Reports (All ER) have three volumes a year. 
For example: 
Robertson v Post Office [1974] 1 WLR 1176 
Ashcroft v Mersey Regional Health Authority [1983] 2 All ER 245 
R v Clarence [1868] 22 QBD 23 
Wimpey Construction UK Ltd v Poole (1984) Times, 3 May 
There are good historical precedents for the use of square and round brackets. Since 
1891, round ones have referred to the date of the report, square ones to the date of 
publication of the report. Apart from not italicising the name of the case, we use the 
lawyers’ style; be careful with punctuation. Here are some more examples: 
Caparo Industries plc v Dickman and others [1990] 1 All ER 568-608. 
R v Clarence [1888] 22 QBD 23. 
Finlayson v HMAdv 1978 SLT (Notes) 60 
Block v Martin (1951) 4 DLR 121 
Official Journal of the European Communities: at the top of the page it gives the No, 
vol, and page and, at the other side of the header, the date. 
The abbreviation for the title is given in parentheses under the title. Jiggle these 
elements around to get, eg: 




Council Directive of 14 June 1989. Offical Journal of the European Communities No L 
1989 June 28:181/44-6. (89/831/EEC. 
 
Digital Object Identifier (DOI) 
A DOI is a unique string created to identify a piece of intellectual property in an online 
environment and is particularly useful for articles that are published online before appearing in 
print (and therefore have not yet been assigned the traditional volume, issue and page number 
references). The DOI is a permanent identifier of all versions of an article, whether raw 
manuscript or edited proof, online or in print. Thus the DOI should ideally be included in the 
citation even if you want to cite a print version of an article. 
Find a DOI  
 
How to cite articles with a DOI before they have appeared in print 
1. Alwick K, Vronken M, de Mos T, et al. Cardiac risk factors: prospective cohort study. Ann 
Rheum DisPublished Online First: 5 February 2004. doi:10.1136/ard.2003.001234 
 
How to cite articles with a DOI once they have appeared in print 
1. Vole P, Smith H, Brown N, et al. Treatments for malaria: randomised controlled trial. Ann 
Rheum Dis2003;327:765–8 doi:10.1136/ard.2003.001234 [published Online First: 5 February 
2002]. 
 
PLEASE NOTE: RESPONSIBILITY FOR THE ACCURACY AND COMPLETENESS 
OF REFERENCES RESTS ENTIRELY WITH THE AUTHOR. 
 
Online only supplementary material 
Additional figures and tables, methodology, raw data, etc may be published online only as 
supplementary material. If your paper exceeds the word count you should consider if any parts 
of the article could be published online only. Please note that these files will not be copyedited 
or typeset and will be published as supplied, therefore PDF files are preferred. 
All supplementary files should be uploaded using the File Designation “Supplementary File”. 
Please ensure that any supplementary files are cited within the main text of the article. 
Some journals also encourage authors to submit translated versions of their abstracts in their 
local language, which are published online only alongside the English version. These should 
be uploaded using the File Designation “Abstract in local language”. 
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